Prestige Consumer Healthcare (PBH) 10-Q 5 Feb 15 2015 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Dec. 31, 2014	Jan. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	1295947
Current Fiscal Year End Date	-28
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		52,273,201

Consolidated_Statements_of_Inc

Consolidated Statements of Income and Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Revenues
Net sales	$196,435	$143,713	$520,981	$450,862
Other revenues	1,171	1,158	3,596	3,466
Total revenues	197,606	144,871	524,577	454,328
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	85,861	64,403	228,424	197,614
Gross profit	111,745	80,468	296,153	256,714
Operating Expenses
Advertising and promotion	30,144	24,229	74,284	67,457
General and administrative	19,454	12,137	63,588	35,390
Depreciation and amortization	5,154	3,644	11,967	10,206
Total operating expenses	54,752	40,010	149,839	113,053
Operating income	56,993	40,458	146,314	143,661
Other (income) expense
Interest income	-20	-16	-67	-44
Interest expense	24,612	21,276	57,505	53,648
Gain on sale of asset	-1,133	0	-1,133	0
Loss on extinguishment of debt	0	15,012	0	15,012
Total other expense	23,459	36,272	56,305	68,616
Income before income taxes	33,534	4,186	90,009	75,045
Provision for income taxes	12,241	1,056	35,521	18,431
Net income	21,293	3,130	54,488	56,614
Earnings per share:
Basic (in USD per share)	$0.41	$0.06	$1.05	$1.10
Diluted (in USD per share)	$0.40	$0.06	$1.04	$1.08
Weighted average shares outstanding:
Basic (in shares)	52,278	51,806	52,110	51,498
Diluted (in shares)	52,730	52,445	52,622	52,236
Comprehensive income, net of tax:
Currency translation adjustments	-8,779	-2,694	-16,883	-1,571
Total other comprehensive loss	-8,779	-2,694	-16,883	-1,571
Comprehensive income	$12,514	$436	$37,605	$55,043

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$21,951	$28,331
Accounts receivable, net	87,692	65,050
Inventories	75,240	65,586
Deferred income tax assets	8,346	6,544
Prepaid expenses and other current assets	7,533	11,674
Total current assets	200,762	177,185
Property and equipment, net	13,089	9,597
Goodwill	291,892	190,911
Intangible assets, net	2,144,084	1,394,817
Other long-term assets	30,769	23,153
Total Assets	2,680,596	1,795,663
Current liabilities
Accounts payable	38,567	48,286
Accrued interest payable	11,792	9,626
Other accrued liabilities	40,675	26,446
Total current liabilities	91,034	84,358
Long-term debt
Principal amount	1,643,600	937,500
Less unamortized discount	-5,639	-3,086
Long-term debt, net of unamortized discount	1,637,961	934,414
Deferred income tax liabilities	342,385	213,204
Other long-term liabilities	279	327
Total Liabilities	2,071,659	1,232,303
Commitments and Contingencies — Note 16
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 52,508 shares at December 31, 2014 and 52,021 shares at March 31, 2014	525	520
Additional paid-in capital	423,985	414,387
Treasury stock, at cost - 255 shares at December 31, 2014 and 206 shares at March 31, 2014	-3,062	-1,431
Accumulated other comprehensive (loss) income, net of tax	-16,144	739
Retained earnings	203,633	149,145
Total Stockholders' Equity	608,937	563,360
Total Liabilities and Stockholders' Equity	$2,680,596	$1,795,663

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Mar. 31, 2014
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$0.01	$0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	52,508,000	52,021,000
Treasury stock, shares	255,000	206,000

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Operating Activities
Net income	$54,488	$56,614
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	11,967	10,209
Gain on sale of asset	-1,133	0
Deferred income taxes	19,517	10,261
Amortization of deferred financing costs	4,568	6,023
Stock-based compensation costs	4,919	3,763
Loss on extinguishment of debt	0	15,012
Premium payment on 2010 Senior Notes	0	-12,768
Amortization of debt discount	1,336	3,115
Lease termination costs	1,125	0
Loss (gain) on sale or disposal of equipment	321	-3
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	2,113	8,495
Inventories	14,478	-2,262
Prepaid expenses and other current assets	7,598	-2,783
Accounts payable	-25,452	-1,285
Accrued liabilities	8,297	-13,531
Net cash provided by operating activities	104,142	80,860
Investing Activities
Purchases of property and equipment	-3,700	-2,658
Proceeds from the sale of property and equipment	0	3
Proceeds from sale of business	18,500	0
Proceeds from sale of asset	10,000	0
Acquisition of Insight Pharmaceuticals, less cash acquired	-749,666	0
Acquisition of the Hydralyte brand	-77,991	0
Acquisition of Care Pharmaceuticals, less cash acquired	0	-55,215
Net cash used in investing activities	-802,857	-57,870
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	0	400,000
Repayment of 2010 Senior Notes	0	-201,710
Term loan borrowings	720,000	0
Term loan repayments	-80,000	-147,500
Borrowings under revolving credit agreement	124,600	50,000
Repayments under revolving credit agreement	-58,500	-45,500
Payment of deferred financing costs	-16,072	-6,933
Proceeds from exercise of stock options	3,654	5,738
Proceeds from restricted stock exercises	57	0
Excess tax benefits from share-based awards	1,030	1,725
Fair value of shares surrendered as payment of tax withholding	-1,688	-278
Net cash provided by financing activities	693,081	55,542
Effects of exchange rate changes on cash and cash equivalents	-746	151
(Decrease) increase in cash and cash equivalents	-6,380	78,683
Cash and cash equivalents - beginning of period	28,331	15,670
Cash and cash equivalents - end of period	21,951	94,353
Interest paid	49,435	47,586
Income taxes paid	$7,135	$9,761

Business_and_Basis_of_Presenta

Business and Basis of Presentation	9 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation
	Nature of Business
	Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada), and in Australia and certain other international markets.  Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 9 to these Consolidated Financial Statements.
	Basis of Presentation
	The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements.  In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2015”) mean our fiscal year ending or ended on March 31st of that year. Operating results for the three and nine months ended December 31, 2014 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2015.  These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.
	Revision
	We revised the classification of certain promotional expenses that were incurred in the prior year to correctly present the amounts as a reduction to net sales. The amounts were not material to any of the periods presented.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates.  As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
	Cash and Cash Equivalents
	We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of our cash is held by a large regional bank with headquarters in California.  We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at December 31, 2014 are uninsured.
	Accounts Receivable
	We extend non-interest-bearing trade credit to our customers in the ordinary course of business.  We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
	Inventories
	Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method.  We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:
		Years
	Machinery	5
	Computer equipment and software	3
	Furniture and fixtures	7
	Leasehold improvements	*
	* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.
	Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.
	Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
	Goodwill
	The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill.  Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.
	Intangible Assets
	Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization.  For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and these assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized.
	Deferred Financing Costs
	We have incurred debt origination costs in connection with the issuance of long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method over the term of the related debt.
	Revenue Recognition
	Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.
	As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered.  At the completion of a promotional program, the estimated amounts are adjusted to actual results.
	Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
	Cost of Sales
	Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.  Shipping, warehousing and handling costs were $9.2 million and $26.3 million for the three and nine months ended December 30, 2014, respectively, and $7.6 million and $23.3 million for the three and nine months ended December 31, 2013, respectively.
	Advertising and Promotion Costs
	Advertising and promotion costs are expensed as incurred.  Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.  Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
	Stock-based Compensation
	We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award.  Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.
	Income Taxes
	Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our uncertainties.
	We are subject to taxation in the United States and various state and foreign jurisdictions.
	We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
	Earnings Per Share
	Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period.  Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period.  Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.
	Recently Issued Accounting Standards
	In January 2015, the FASB issued Accounting Standards Update ("ASU") 2015-01. The amendments in this update eliminate the concept of extraordinary items in Subtopic 225-20, which required entities to consider whether an underlying event or transaction is extraordinary. However, the amendments retain the presentation and disclosure guidance for items that are unusual in nature or occur infrequently. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of ASU 2015-01 is not expected to have a material impact on our Consolidated Financial Statements.
	In November 2014, the FASB issued ASU 2014-17, Pushdown Accounting, which clarifies whether and at what threshold an acquired entity that is a business or nonprofit activity can apply pushdown accounting in its separate financial statements. This ASU provides companies with the option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. The election to apply pushdown accounting can be made either in the period in which the change of control occurred, or in a subsequent period. The amendments in this update were effective November 18, 2014. The adoption of ASU 2014-17 did not have a material impact on our Consolidated Financial Statements.
	In November 2014, the FASB issued ASU 2014-16, Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity. The amendments in this update clarify how current GAAP should be interpreted in evaluating economic characteristics and risks and ultimately determining whether the host contract in a hybrid financial instrument that is issued in the form of a share is more akin to debt or to equity. The effects of initially adopting the amendments in this update should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. The amendments in this update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2014-16 is not expected to have a material impact on our Consolidated Financial Statements.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.
	In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are evaluating the impact of adopting this prospective guidance on our consolidated results of operations and financial condition.
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.
	Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Acquisitions

Acquisitions	9 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Acquisitions	Acquisitions
	Acquisition of Insight Pharmaceuticals
	On September 3, 2014, the Company completed its previously announced acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $753.2 million in cash. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extends the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat, the leading brand in OTC yeast infection treatment. The acquisition also adds brands to the Company's cough/cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, we sold one of the competing brands that we acquired from Insight on the same day as the Insight closing. Insight is primarily included in our North America OTC Healthcare segment.
	The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.
	We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.
	(In thousands)	3-Sep-14
	Cash acquired	$	3,507
	Accounts receivable	25,784
	Inventories	23,559
	Deferred income tax assets - current	860
	Prepaids and other current assets	1,407
	Property, plant and equipment	2,308
	Goodwill	103,255
	Intangible assets	724,374
	Total assets acquired	885,054
	Accounts payable	16,079
	Accrued expenses	8,003
	Deferred income tax liabilities - long term	107,799
	Total liabilities assumed	131,881
	Total purchase price	$	753,173
	Based on this analysis, we allocated $599.6 million to non-amortizable intangible assets and $124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at December 31, 2014 was 15.9 years.
	We also recorded goodwill of $103.3 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.
	The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. Revenues of the acquired Insight operations for the three and nine months ended December 31, 2014 were $43.4 million and $56.1 million, respectively. Net income for the three and nine months ended December 31, 2014 was $3.6 million and $1.6 million, respectively. On September 3, 2014, we sold one of the brands we acquired from the Insight acquisition for $18.5 million, for which we had allocated $17.7 million, $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively.
	The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.
	(In thousands, except per share data)		Nine Months Ended December 31, 2014
	Revenues		$	593,171
	Net income		$	62,688
	Earnings per share:
	Basic		$	1.2
	Diluted		$	1.19
	(In thousands, except per share data)		Nine Months Ended December 31, 2013
	Revenues		$	579,762
	Net income		$	57,537
	Earnings per share:
	Basic		$	1.12
	Diluted		$	1.1
	Acquisition of the Hydralyte brand
	On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on hand and our existing senior secured credit facility.
	Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment.
	The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.
	We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.
	(In thousands)	30-Apr-14
	Inventories	$	1,970
	Property, plant and equipment, net	1,267
	Goodwill	1,224
	Intangible assets, net	73,580
	Total assets acquired	78,041
	Accrued expenses	38
	Other long term liabilities	12
	Total liabilities assumed	50
	Net assets acquired	$	77,991
	Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets.
	We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is not deductible for income tax purposes.
	The pro forma effect of this acquisition on revenues and earnings was not material.
	Acquisition of Care Pharmaceuticals Pty Ltd.
	On July 1, 2013, we completed the acquisition of Care Pharma, which was funded through a combination of our existing senior secured credit facility and cash on hand.
	The Care Pharma brands include the Fess line of cold/allergy and saline nasal health products, which is the leading saline spray for both adults and children in Australia. Other key brands include Painstop analgesic, Rectogesic for rectal discomfort, and the Fab line of nutritional supplements. Care Pharma also includes a line of brands for children including Little Allergies, Little Eyes, and Little Coughs. The brands acquired are complementary to our OTC Healthcare portfolio and are included in our International OTC Healthcare segment.
	The Care Pharma acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition.
	We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.
	(In thousands)	1-Jul-13
	Cash acquired	$	1,546
	Accounts receivable	1,658
	Inventories	2,465
	Deferred income taxes	283
Prepaids and other current assets	647
Property, plant and equipment	163
Goodwill	23,122
Intangible assets	31,502
Total assets acquired	61,386
Accounts payable	1,537
Accrued expenses	2,788
Other long term liabilities	300
Total liabilities assumed	4,625
Net assets acquired	$	56,761
Based on this analysis, we allocated $29.8 million to non-amortizable intangible assets and $1.7 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 15.1 years. The weighted average remaining life for amortizable intangible assets at December 31, 2014 was 12.3 years.
We also recorded goodwill of $23.1 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. The full amount of goodwill is deductible for income tax purposes.
The pro forma effect of this acquisition on revenues and earnings was not material.

Accounts_Receivable

Accounts Receivable	9 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Accounts Receivable	Accounts Receivable
	Accounts receivable consist of the following:
	(In thousands)	December 31,			March 31,
		2014			2014
	Components of Accounts Receivable
	Trade accounts receivable	$	95,596		$	73,632
	Other receivables	2,998			1,360
		98,594			74,992
	Less allowances for discounts, returns and uncollectible accounts	(10,902		)	(9,942		)
	Accounts receivable, net	$	87,692		$	65,050

Inventories

Inventories	9 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	Inventories
	Inventories consist of the following:
	(In thousands)	December 31,		March 31,
		2014		2014
	Components of Inventories
	Packaging and raw materials	$	6,909	$	3,099
	Finished goods	68,331		62,487
	Inventories	$	75,240	$	65,586
	Inventories are carried at the lower of cost or market, which includes a reduction in inventory values of $4.4 million and $1.1 million at December 31, 2014 and March 31, 2014, respectively, related to obsolete and slow-moving inventory. Following the acquisition of the Hydralyte brand on April 30, 2014, we manufacture certain Hydralyte products in Australia.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment
	Property and equipment consist of the following:
	(In thousands)	December 31,			March 31,
		2014			2014
	Components of Property and Equipment
	Machinery	$	4,313		$	1,927
	Computer equipment and software	9,950			8,923
	Furniture and fixtures	2,427			1,858
	Leasehold improvements	6,705			4,734
		23,395			17,442
	Accumulated depreciation	(10,306		)	(7,845		)
	Property and equipment, net	$	13,089		$	9,597
	We recorded depreciation expense of $1.0 million and $1.1 million for the three months ended December 31, 2014 and December 31, 2013, respectively, and $2.6 million and $2.2 million for the nine months ended December 31, 2014 and December 31, 2013, respectively.

Goodwill

Goodwill	9 Months Ended
	Dec. 31, 2014
Goodwill [Abstract]
Goodwill	Goodwill
	As described in Note 18 to these Consolidated Financial Statements, we have realigned our reportable segments effective April 1, 2014 with how we currently operate, review and evaluate the results of our business. A reconciliation of the activity affecting goodwill by reportable segment is as follows:
	(In thousands)	North American OTC		International OTC			Household			Consolidated
		Healthcare		Healthcare			Cleaning
	Balance — March 31, 2014	$	160,157	$	23,365		$	7,389		$	190,911
	Additions	103,254		1,224			—			104,478
	Reductions	—		—			(589		)	(589		)
	Effects of foreign currency exchange rates	—		(2,908		)	—			(2,908		)
	Balance — December 31, 2014	$	263,411	$	21,681		$	6,800		$	291,892
	As discussed in Note 2, we completed two acquisitions during the nine months ended December 31, 2014. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $103.3 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired.
	As further discussed in Note 7, in December 2014, we completed a transaction to sell rights to use of the Comet brand in certain Eastern European countries to a third-party licensee. As a result, we recorded a gain on sale of $1.3 million and reduced the carrying value of our intangible assets and goodwill.
	Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount.
	On an annual basis, during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment.
	At March 31, 2014, during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2014. As of December 31, 2014, there have been no triggering events that would indicate potential impairment of goodwill.
	The discounted cash flow methodology is a widely-accepted valuation technique to estimate fair value that is utilized by market participants in the transaction evaluation process and has been applied consistently. We also considered our market capitalization at March 31, 2014, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future.

Intangible_Assets

Intangible Assets	9 Months Ended
	Dec. 31, 2014
Intangible Assets [Abstract]
Intangible Assets	Intangible Assets
	A reconciliation of the activity affecting intangible assets is as follows:
	(In thousands)	Indefinite			Finite Lived			Totals
		Lived			Trademarks
		Trademarks
	Gross Carrying Amounts
	Balance — March 31, 2014	$	1,273,878		$	204,740		$	1,478,618
	Additions	673,180			124,774			797,954
	Reductions	(9,548		)	(17,674		)	(27,222		)
	Effects of foreign currency exchange rates	(12,371		)	(197		)	(12,568		)
	Balance — December 31, 2014	1,925,139			311,643			2,236,782
	Accumulated Amortization
	Balance — March 31, 2014	—			83,801			83,801
	Additions	—			8,915			8,915
	Effects of foreign currency exchange rates	—			(18		)	(18		)
	Balance — December 31, 2014	—			92,698			92,698
	Intangible assets, net - December 31, 2014	$	1,925,139		$	218,945		$	2,144,084
	Intangible Assets, net by Reportable Segment:
	North American OTC Healthcare	$	1,723,498		$	192,756		$	1,916,254
	International OTC Healthcare	91,369			1,330			92,699
	Household Cleaning	110,272			24,859			135,131
	Intangible assets, net - December 31, 2014	$	1,925,139		$	218,945		$	2,144,084
	As discussed in Note 2, we completed two acquisitions during the nine months ended December 31, 2014. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our preliminary analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our preliminary analysis. Furthermore, on September 3, 2014 we sold one of the brands that we acquired from Insight, for which we allocated $17.7 million to the intangible assets.
	Sale of asset
	Historically, we received royalty income from the licensing of the name of certain of our brands in geographic areas or markets in which we do not directly compete. We have had a royalty agreement for our Comet brand for several years, which included an option on behalf of the licensee to purchase the rights in certain geographic areas and markets in perpetuity. In December 2014, we amended the agreement to allow the licensee to buy out a portion of the agreement early, but retaining the remaining stream of royalty payments. In December, in connection with this amendment, we sold rights to use of the Comet brand in certain Eastern European countries to a third-party licensee and received $10.0 million as a partial early buyout. As a result, we recorded a gain on sale of $1.3 million, and reduced the carrying value of our intangible assets and goodwill. The licensee will continue to make quarterly payments at least through June 30, 2016 of approximately $1.0 million. The licensee has the option to purchase the remaining territories and markets, as defined in the agreement, at any time after July 1, 2016.
	Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount.  Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life.  Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.
	On an annual basis during the fourth fiscal quarter, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment.
	In a manner similar to goodwill, we completed our annual test for impairment of our indefinite-lived intangible assets during the fourth quarter of fiscal 2014.
	We have experienced declines in revenues and profitability of certain brands in the North American OTC Healthcare segment during the three and nine months ended December 31 2014, compared to the same periods during the prior year. Sustained or significant future declines in revenue, profitability, other adverse changes in expected operating results, and/or unfavorable changes in other economic factors used to estimate fair values of certain brands could indicate that fair value no longer exceeds the carrying value, in which case a non-cash impairment charge may be recorded in future periods. In particular, we continue to experience increasing competitive pressures for certain brands within our pediatric cough and cold and gastrointestinal product groups. Specifically in the cough and cold product group, we expected revenues to decline with the return to the market of competing products. However, such declines have been steeper than expected. Current quarter and year-to-date revenues from our Pediacare brand have declined significantly as compared to the corresponding periods in the prior year, due primarily to competition in the category, including new product introductions and lost distribution. As a result, we have increased our promotional spending in the short term, which resulted in lower revenues and profitability. Based on these factors, we considered whether these conditions would indicate that the fair value of the reporting unit would no longer exceed the carrying value, and accordingly, we performed an interim impairment analysis.
	Based on completion of step 1 of the impairment analysis for goodwill and indefinite-lived intangible assets, the fair value of the Pediacare reporting unit and trademarks, exceed their book value and therefore, we concluded that no impairment existed as of December 31, 2014 and that step 2 of the impairment test was not required. The carrying value for the Pediacare reporting unit at December 31, 2014 is approximately $45.8 million. See Item 2, Critical Accounting Policies for a further discussion on the assumptions used in our impairment analysis.
	Additionally, for all indefinite-lived intangible assets, an evaluation of the facts and circumstances as of December 31, 2014 continues to support an indefinite useful life for such assets. Therefore, no impairment charge was recorded for the nine months ended December 31, 2014, as facts and circumstances indicated that the fair values of the intangible assets for our brands exceeded their carrying values.
	The weighted average remaining life for finite-lived intangible assets at December 31, 2014 was approximately 14.1 years and the amortization expense for the three and nine months ended December 31, 2014 was $3.9 million and $8.9 million, respectively. At December 31, 2014, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:
	(In thousands)
	Year Ending March 31,		Amount
	2015 (Remaining three months ending March 31, 2015)		$	3,887
	2016		15,547
	2017		15,547
	2018		15,547
	2019		15,547
	Thereafter		152,870
			$	218,945

Other_Accrued_Liabilities

Other Accrued Liabilities	9 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities
	Other accrued liabilities consist of the following:
	(In thousands)	December 31,		March 31,
		2014		2014
	Accrued marketing costs	$	19,413	$	11,812
	Accrued compensation costs	6,455		6,232
	Accrued broker commissions	1,484		1,019
	Income taxes payable	2,163		1,854
	Accrued professional fees	2,999		2,002
	Deferred rent	1,060		1,258
	Accrued production costs	4,390		1,506
	Accrued lease termination costs	1,110		—
	Other accrued liabilities	1,601		763
		$	40,675	$	26,446

LongTerm_Debt

Long-Term Debt	9 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt
	2012 Senior Notes:
	On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes.
	2012 Term Loan and 2012 ABL Revolver:
	On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a seven-year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a five-year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25%. The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million. In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company.
	On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under the Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin. The new Term B-1 Loans mature on the same date as the Term B Loans' original maturity date.  In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt.
	On September 3, 2014, the Borrower entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provides for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million, (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin, and (y) the Term B-2 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00%, or an alternate base rate, with a floor of 2.00%, plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio).
	The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 2.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 1.00%. For the nine months ended December 31, 2014, the average interest rate on the 2012 Term Loan was 5.2%.
	Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we have previously made significant optional payments that exceeded all of our required quarterly payments, we will not be required to make a payment until the maturity date of January 31, 2019.
	On September 3, 2014, the Borrower entered into Amendment No. 3 (“ABL Amendment No. 3”) to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50%, (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the nine months ended December 31, 2014, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 3.1%.
	2013 Senior Notes:
	On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes.
	Redemptions and Restrictions:
	At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we may redeem up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.
	At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.
	The indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At December 31, 2014, we were in compliance with the covenants under our long-term indebtedness.
	At December 31, 2014, we had an aggregate of $30.6 million of unamortized debt issuance costs and $5.6 million of unamortized debt discount, the total of which is comprised of $9.0 million related to the 2012 Senior Notes, $6.4 million related to the 2013 Senior Notes, $19.7 million related to the 2012 Term Loan, and $1.1 million related to the 2012 ABL Revolver.
	During the nine months ended December 31, 2014, we borrowed a net amount of $66.1 million against the 2012 ABL Revolver.
	Long-term debt consists of the following, as of the dates indicated:
	(In thousands, except percentages)	December 31,			March 31,
		2014			2014
	2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
	2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
	2012 Term B-1 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on January 31, 2019.	247,500			287,500
	2012 Term B-2 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on September 3, 2021.	680,000			—
	2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	66,100			—
		1,643,600			937,500
	Current portion of long-term debt	—			—
		1,643,600			937,500
	Less: unamortized discount	(5,639		)	(3,086		)
	Long-term debt, net of unamortized discount	$	1,637,961		$	934,414
	As of December 31, 2014, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:
	(In thousands)
	Year Ending March 31,	Amount
	2015 (remaining three months ending March 31, 2015)	$	—
	2016	—
	2017	66,100
	2018	—
	2019	247,500
	Thereafter	1,330,000
		$	1,643,600

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.
	The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created:
	Level 1 - Quoted market prices for identical instruments in active markets;
	Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and
	Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant.
	The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the Term B-1 Loans, Term B-2 Loans, the 2013 Senior Notes, the 2012 Senior Notes, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At December 31, 2014 and March 31, 2014, we did not have any assets or liabilities measured in Level 1 or 3. During any of the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3.
	At December 31, 2014 and March 31, 2014, the carrying value of our 2013 Senior Notes was $400.0 million. The fair value of our 2013 Senior Notes was $391.5 million and $408.5 million at December 31, 2014 and March 31, 2014, respectively.
	At December 31, 2014 and March 31, 2014, the carrying value of our 2012 Senior Notes was $250.0 million. The fair value of our 2012 Senior Notes was $264.1 million and $280.6 million at December 31, 2014 and March 31, 2014, respectively.
	At December 31, 2014 and March 31, 2014, the carrying value of the Term B-1 Loans was $247.5 million and $287.5 million, respectively. The fair value of the Term B-1 Loans was $246.9 million and $288.9 million at December 31, 2014 and March 31, 2014, respectively.
	At December 31, 2014 the carrying value of the Term B-2 Loans was $680.0 million. The fair value of the Term B-2 Loan was $680.0 million at December 31, 2014. Because the Term B-2 Loans was entered into on September 3, 2014, there were no outstanding loan balances as of March 31, 2014.
	At December 31, 2014, the carrying value and fair value of the 2012 ABL Revolver was $66.1 million and $65.4 million, respectively. There were no outstanding borrowings under the 2012 ABL Revolver at March 31, 2014.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity
	The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share.  The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.
	Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders.  The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends.  No dividends have been declared or paid on the Company's common stock through December 31, 2014.
	During the three and nine months ended December 31, 2014, we repurchased 781 shares and 48,445 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. During the three and nine months ended December 31, 2013, we repurchased 2,549 shares and 13,275 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the nine months ended December 31, 2014 and 2013 were at an average price of $33.66 and $27.81, respectively. All of the repurchased shares have been recorded as treasury stock.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive (Loss) Income	9 Months Ended
	Dec. 31, 2014
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive (Loss) Income	Accumulated Other Comprehensive (Loss) Income
	The table below presents accumulated other comprehensive (loss) income (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners.
	AOCI consisted of the following at December 31, 2014 and March 31, 2014:
		December 31,			March 31,
	(In thousands)	2014			2014
	Components of Accumulated Other Comprehensive (Loss) Income
	Cumulative translation adjustment	$	(16,144	)	$	739
	Total accumulated other comprehensive (loss) income, net of tax	$	(16,144	)	$	739

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share
	Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, restricted stock awards, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share:
		Three Months Ended December 31,				Nine Months Ended December 31,
	(In thousands, except per share data)	2014		2013		2014		2013
	Numerator
	Net income	$	21,293	$	3,130	$	54,488	$	56,614
	Denominator
	Denominator for basic earnings per share — weighted average shares outstanding	52,278		51,806		52,110		51,498
	Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	452		639		512		738
	Denominator for diluted earnings per share	52,730		52,445		52,622		52,236
	Earnings per Common Share:
	Basic net earnings per share	$	0.41	$	0.06	$	1.05	$	1.1
	Diluted net earnings per share	$	0.4	$	0.06	$	1.04	$	1.08
	For the three months ended December 31, 2014 and 2013, there were 0.3 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the nine months ended December 31, 2014 and 2013, there were 0.3 million and 0.2 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation
	In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for the grant of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. On June 19, 2014, the Board of Directors amended the Plan to provide for the grant of an additional 1.8 million shares of the Company's stock, $0.01 par value, pursuant to the Plan, which amendment the Company's stockholders approved on August 5, 2014.  Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan.
	During the three and nine months ended December 31, 2014, pre-tax share-based compensation costs charged against income were $1.5 million and $4.9 million, respectively, and the related income tax benefit recognized was $0.6 million and $1.8 million, respectively. During the three and nine months ended December 31, 2013, pre-tax share-based compensation costs charged against income were $1.3 million and $3.8 million, respectively, and the related income tax benefit recognized was $0.4 million and $1.1 million, respectively.
	Restricted Shares
	Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals by the Company, including revenue and earnings before income taxes, depreciation and amortization targets.  The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan.  The restricted stock units granted to employees generally vest in their entirety on the three-year anniversary of the date of the grant, unless specified differently on the date of grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units. The restricted stock units granted to directors will vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock.
	On May 12, 2014, the Compensation Committee of our Board of Directors granted 96,638 restricted stock units to certain executive officers and employees under the Plan. Of those grants, 75,638 restricted stock units vest in their entirety on the three-year anniversary of the date of grant and 21,000 restricted stock units vest 33.3% per year over three years.
	The fair value of the restricted stock units is determined using the closing price of our common stock on the day of grant. The weighted-average grant-date fair value of restricted stock units granted during the nine months ended December 31, 2014 and 2013 was $33.30 and $30.19, respectively.
	A summary of the Company's restricted shares granted under the Plan is presented below:
					Weighted-
		Shares			Average
		(in thousands)			Grant-Date
	Restricted Shares				Fair Value
	Nine months ended December 31, 2013
	Vested and nonvested at March 31, 2013	421.3			$	11.01
	Granted	126.6			30.19
	Vested and issued	(59.7	)		8.42
	Forfeited	(5.6	)		15.11
	Vested and nonvested at December 31, 2013	482.6			16.32
	Vested at December 31, 2013	83.1			9.63
	Nine months ended December 31, 2014:
	Vested and nonvested at March 31, 2014	437.5			$	16.76
	Granted	104.4			33.3
	Vested and issued	(122.8	)		13.62
	Forfeited	(21.3	)		20.77
	Vested and nonvested at December 31, 2014	397.8			21.86
	Vested at December 31, 2014	76.6			11.62
	Options
	The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted.  Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally over three to five years.  The option awards provide for accelerated vesting if there is a change in control, as defined in the Plan.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below.  Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies.  We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors.  Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation.  The expected terms of the options granted are derived from management's estimates and consideration of information derived from the public filings of companies similar to us and represent the period of time that options granted are expected to be outstanding.  The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option.  On May 12, 2014, the Compensation Committee of our Board of Directors granted stock options to acquire 307,490 shares of our common stock to certain executive officers and employees under the Plan. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $33.50 per share, which is equal to the closing price for our common stock on the date of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan.
	The weighted-average grant-date fair value of the options granted during the nine months ended December 31, 2014 and 2013 was $15.93 and $13.94, respectively.
		Nine Months Ended December 31,
		2014				2013
	Expected volatility	47.3		%		48		%
	Expected dividends	$	—			$	—
	Expected term in years	6				6
	Risk-free rate	2.2		%		1.3		%
	A summary of option activity under the Plan is as follows:
					Weighted-				Weighted-	Aggregate
					Average				Average	Intrinsic
		Shares			Exercise				Remaining	Value
		(in thousands)			Price				Contractual	(in thousands)
	Options								Term
	Nine months ended December 31, 2013:
	Outstanding at March 31, 2013	1,386.40			$	10.43
	Granted	227.7			29.94
	Exercised	(589.9	)		9.73
	Forfeited or expired	(14.2	)		14.56
	Outstanding at December 31, 2013	1,010.00			15.18				7.6	$	20,828
	Exercisable at December 31, 2013	172.1			11.34				6.8	4,210
	Nine months ended December 31, 2014:
	Outstanding at March 31, 2014	994.9			$	15.24
	Granted	307.5			33.5
	Exercised	(363.4	)		10.05
	Forfeited or expired	(47.5	)		25.76
	Outstanding at December 31, 2014	891.5			23.09				7.9	$	10,368
	Exercisable at December 31, 2014	335.1			15.01				6.7	6,604
	The aggregate intrinsic value of options exercised in the nine months ended December 31, 2014 was $8.8 million.
	At December 31, 2014, there were $5.9 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest.  We expect to recognize such costs over a weighted-average period of 0.9 years.  The total fair value of options and restricted shares vested during the nine months ended December 31, 2014 and 2013 was $4.3 million and $3.2 million, respectively.  For the nine months ended December 31, 2014 and 2013, cash received from the exercise of stock options was $3.7 million and $5.7 million, respectively, and we realized $1.9 million and $1.7 million, respectively, in tax benefits from the tax deductions resulting from these option exercises. At December 31, 2014, there were 1.2 million shares available for issuance under the Plan.

Income_Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur.  The effective tax rates used in the calculation of income taxes were 36.5% and 25.2% for the three months ended December 31, 2014 and December 31, 2013, respectively. The effective tax rates used in the calculation of income taxes were 39.5% and 24.6% for the nine months ended December 31, 2014 and December 31, 2013, respectively. The increase in the effective tax rate for the three and nine months ended December 31, 2014 was primarily due to the impact of certain non-deductible items related to acquisitions, and a higher gain for tax purposes associated with the sale of the right of use of the Comet brand in the current period and a one-time benefit of $9.1 million due primarily to lower state income taxes enacted in the prior year period. This benefit was primarily related to a law change in the state where we have our major distribution center to tax earnings attributed to in-state revenues only.
	At December 31, 2014, wholly-owned subsidiaries of the Company had net operating loss carryforwards of approximately $69.8 million, which may be used to offset future taxable income of the consolidated group and which begin to expire in 2020.  The net operating loss carryforwards are subject to an annual limitation as to usage of approximately $33.6 million pursuant to Internal Revenue Code Section 382. The Company expects to utilize all of the net operating loss carryforwards before they expire.
	We had a net increase of $0.5 million in our uncertain tax liability during the nine months ended December 31, 2014. Therefore, the balance in our uncertain tax liability was $1.7 million at December 31, 2014 and $1.2 million at March 31, 2014. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense.  We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	We are involved from time to time in legal matters and other claims incidental to our business.  We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss.  These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted.  The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our financial condition or results of operations.
	Lease Commitments
	We have operating leases for office facilities and equipment in New York, Wyoming, and other locations, which expire at various dates through fiscal 2021. We required additional office space as a result of the closing of the acquisition of Insight. Therefore, in the first quarter of fiscal 2015, we amended our existing New York office lease to include an additional 15,470 square feet beginning October 2014 and extended the expiration of the combined lease through September 2020. These amounts have been included in the table below.
	The following summarizes future minimum lease payments for our operating leases as of December 31, 2014:
	(In thousands)
	Year Ending March 31,	Facilities		Equipment		Total
	2015 (Remaining three months ending March 31, 2015)	$	422	$	274	$	696
	2016	1,612		311		1,923
	2017	1,772		77		1,849
	2018	1,856		—		1,856
	2019	1,864		—		1,864
	Thereafter	2,465		—		2,465
		$	9,991	$	662	$	10,653
	Rent expense for the three months ended December 31, 2014 and 2013 was $0.4 million and $0.4 million, respectively, while rent expense for the nine months ended December 31, 2014 and 2013 was $1.2 million and $1.2 million, respectively.
	Purchase Commitments
	Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products.  Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.
	(In thousands)
	Year Ending March 31,	Amount
	2015 (Remaining three months ending March 31, 2015)	273
	2016	1,074
	2017	1,044
	2018	1,013
	2019	982
	Thereafter	560
		$	4,946

Concentrations_of_Risk

Concentrations of Risk	9 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk
	Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products.  We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores.  During the three and nine months ended December 31, 2014, approximately 44.3% and 41.9%, respectively, of our total revenues were derived from our five top selling brands.  During the three and nine months ended December 31, 2013, approximately 41.1% and 41.7%, respectively, of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 16.5% and 17.4%, respectively, of our gross revenues for the three and nine months ended December 31, 2014, and approximately 20.4% and 19.7%, respectively, of our gross revenues for the three and nine months ended December 31, 2013. At December 31, 2014, approximately 20.2% and 13.4% of accounts receivable were owed by Walmart and Walgreens, respectively.
	We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri.  A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost.  We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center and inventory levels.  As a result, any such disruption could have a material adverse effect on our business, sales and profitability.
	At December 31, 2014, we had relationships with 96 third-party manufacturers.  Of those, we had long-term contracts with 44 manufacturers that produced items that accounted for approximately 80.1% of gross sales for the nine months ended December 31, 2014. At December 31, 2013, we had relationships with 58 third-party manufacturers.  Of those, we had long-term contracts with 21 manufacturers that produced items that accounted for approximately 86.3% of gross sales for the nine months ended December 31, 2013. The fact that we do not have long-term contracts with certain manufacturers means they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business, financial condition and results from operations.

Business_Segments

Business Segments	9 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Business Segments	Business Segments
	Beginning April 1, 2014, we began managing and reporting certain of our businesses separately and have therefore realigned our reportable segments to align with how we manage and evaluate the results of our business. These reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. The results of our previously reported OTC Healthcare segment is now separated into two reporting segments, the North American OTC Healthcare segment and the International OTC Healthcare segment, largely to reflect our international expansion due to recent acquisitions. Prior year amounts were reclassified to conform to the current reportable segments discussed above. Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses.
	The tables below summarize information about our reportable segments.
		Three Months Ended December 31, 2014
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	160,655		$	17,071	$	20,218	$	197,944
	Elimination of intersegment revenues	(1,509		)	—		—		(1,509		)
	Third-party segment revenues	159,146			17,071		20,218		196,435
	Other revenues	151			4		1,016		1,171
	Total segment revenues	159,297			17,075		21,234		197,606
	Cost of sales	63,479			6,247		16,135		85,861
	Gross profit	95,818			10,828		5,099		111,745
	Advertising and promotion	26,779			2,776		589		30,144
	Contribution margin	$	69,039		$	8,052	$	4,510	81,601
	Other operating expenses								24,608
	Operating income								56,993
	Other expense								23,459
	Income before income taxes								33,534
	Provision for income taxes								12,241
	Net income								$	21,293
		Nine Months Ended December 31, 2014
	(In thousands)	North			International		Household		Consolidated
		American			OTC		Cleaning
		OTC			Healthcare
		Healthcare
	Gross segment revenues	$	409,767		$	48,093	$	66,057	$	523,917
	Elimination of intersegment revenues	(2,936		)	—		—		(2,936		)
	Third-party segment revenues	406,831			48,093		66,057		520,981
	Other revenues	478			62		3,056		3,596
	Total segment revenues	407,309			48,155		69,113		524,577
	Cost of sales	158,005			17,926		52,493		228,424
	Gross profit	249,304			30,229		16,620		296,153
	Advertising and promotion	64,573			8,151		1,560		74,284
	Contribution margin	$	184,731		$	22,078	$	15,060	221,869
	Other operating expenses								75,555
	Operating income								146,314
	Other expense								56,305
	Income before income taxes								90,009
	Provision for income taxes								35,521
	Net income								$	54,488
		Three Months Ended December 31, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	117,476		$	8,214	$	19,532	$	145,222
	Elimination of intersegment revenues	(1,509		)	—		—		(1,509		)
	Third-party segment revenues	115,967			8,214		19,532		143,713
	Other revenues	150			—		1,008		1,158
	Total segment revenues	116,117			8,214		20,540		144,871
	Cost of sales	45,886			3,144		15,373		64,403
	Gross profit	70,231			5,070		5,167		80,468
	Advertising and promotion	21,380			2,145		704		24,229
	Contribution margin	$	48,851		$	2,925	$	4,463	56,239
	Other operating expenses								15,781
	Operating income								40,458
	Other expense								36,272
	Income before income taxes								4,186
	Provision for income taxes								1,056
	Net income								$	3,130
		Nine Months Ended December 31, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	369,356		$	20,636	$	63,198	$	453,190
	Elimination of intersegment revenues	(2,328		)	—		—		(2,328		)
Third-party segment revenues	367,028			20,636		63,198		450,862
Other revenues	450			14		3,002		3,466
Total segment revenues	367,478			20,650		66,200		454,328
Cost of sales	140,419			8,947		48,248		197,614
Gross profit	227,059			11,703		17,952		256,714
Advertising and promotion	61,477			3,855		2,125		67,457
Contribution margin	$	165,582		$	7,848	$	15,827	189,257
Other operating expenses								45,596
Operating income								143,661
Other expense								68,616
Income before income taxes								75,045
Provision for income taxes								18,431
Net income								$	56,614
The tables below summarize information about our segment revenues from similar product groups.
	Three Months Ended December 31, 2014
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Analgesics	$	28,187		$	657	$	—	$	28,844
Cough & Cold	31,927			3,831		—		35,758
Women's Health	31,364			589		—		31,953
Gastrointestinal	17,365			6,668		—		24,033
Eye & Ear Care	19,020			4,577		—		23,597
Dermatologicals	17,663			570		—		18,233
Oral Care	12,300			172		—		12,472
Other OTC	1,471			11		—		1,482
Household Cleaning	—			—		21,234		21,234
Total segment revenues	$	159,297		$	17,075	$	21,234	$	197,606
	Nine Months Ended December 31, 2014
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Analgesics	$	82,290		$	2,114	$	—	$	84,404
Cough & Cold	76,741			14,090		—		90,831
Women's Health	40,851			1,765		—		42,616
Gastrointestinal	58,899			14,764		—		73,663
Eye & Ear Care	61,150			13,247		—		74,397
Dermatologicals	47,383			1,799		—		49,182
Oral Care	35,421			361		—		35,782
Other OTC	4,574			15		—		4,589
Household Cleaning	—			—		69,113		69,113
Total segment revenues	$	407,309		$	48,155	$	69,113	$	524,577
	Three Months Ended December 31, 2013
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Analgesics	$	25,117		$	648	$	—	$	25,765
Cough & Cold	29,863			3,738		—		33,601
Women's Health	404			619		—		1,023
Gastrointestinal	19,420			272		—		19,692
Eye & Ear Care	16,973			2,244		—		19,217
Dermatologicals	11,019			497		—		11,516
Oral Care	11,125			196		—		11,321
Other OTC	2,196			—		—		2,196
Household Cleaning	—			—		20,540		20,540
Total segment revenues	$	116,117		$	8,214	$	20,540	$	144,871
	Nine Months Ended December 31, 2013
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Analgesics	$	82,596		$	1,375	$	—	$	83,971
Cough & Cold	78,791			9,745		—		88,536
Women's Health	1,392			1,252		—		2,644
Gastrointestinal	62,873			583		—		63,456
Eye & Ear Care	56,949			6,128		—		63,077
Dermatologicals	43,366			1,194		—		44,560
Oral Care	35,238			373		—		35,611
Other OTC	6,273			—		—		6,273
Household Cleaning	—			—		66,200		66,200
Total segment revenues	$	367,478		$	20,650	$	66,200	$	454,328
During the three months ended December 31, 2014 and December 31, 2013, approximately 85.9% and 85.7%, respectively, of our total segment revenues were from customers in the United States. During the nine months ended December 31, 2014 and December 31, 2013, approximately 84.4% and 87.2%, respectively, of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three months ended December 31, 2014, our Canada and Australia sales accounted for approximately 5.1% and 7.2%, respectively, of our total segment revenues, while during the three months ended December 31, 2013, approximately 8.3% of our total segment revenues was attributable to sales to Canada. During the nine months ended December 31, 2014, our Canada and Australia sales accounted for approximately 6.1% and 7.5%, respectively, of our total segment revenues, while during the nine months ended December 31, 2013, approximately 7.8% of our total segment revenues was attributable to sales to Canada.
At December 31, 2014, approximately 95.3% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.7% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:
(In thousands)	North American OTC			International OTC		Household		Consolidated
	Healthcare			Healthcare		Cleaning
Goodwill	$	263,411		$	21,681	$	6,800	$	291,892
Intangible assets
Indefinite-lived	1,723,498			91,369		110,272		1,925,139
Finite-lived	192,756			1,330		24,859		218,945
Intangible assets, net	1,916,254			92,699		135,131		2,144,084
Total	$	2,179,665		$	114,380	$	141,931	$	2,435,976

Condensed_Consolidating_Financ

Condensed Consolidating Financial Statements	9 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Financial Statements	Condensed Consolidating Financial Statements
	As described in Note 9, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes and the 2012 Senior Notes, including the obligation to pay principal and interest with respect to the 2013 Senior Notes and the 2012 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes and the 2012 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, and Blacksmith Brands, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes and the 2012 Senior Notes. Although holders of the 2013 Senior Notes and the 2012 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes and the 2012 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes or the 2012 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes or the 2012 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes and the 2012 Senior Notes.
	Presented below are supplemental Condensed Consolidating Balance Sheets as of December 31, 2014 and March 31, 2014, Condensed Consolidating Statements of Income and Comprehensive Income for the three and nine months ended December 31, 2014 and 2013, and Condensed Consolidating Statements of Cash Flows for the nine months ended December 31, 2014 and 2013. Such consolidating information includes separate columns for:
	a)  Prestige Brands Holdings, Inc., the parent,
	b)  Prestige Brands, Inc., the Issuer or the Borrower,
	c)  Combined Subsidiary Guarantors,
	d)  Combined Non-Guarantor Subsidiaries, and
	e)  Elimination entries necessary to consolidate the Company and all of its subsidiaries.
	The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q.
	In the third quarter of fiscal 2014, the Company determined that it had incorrectly recorded certain intercompany transactions relating to the second quarter of fiscal 2014. This resulted in an understatement of equity in earnings of subsidiaries for Prestige Brands, Inc. of $48.1 million, an overstatement of $0.6 million for Prestige Brands Holdings, Inc. and a net understatement of equity in earnings of subsidiaries for the eliminations of $47.5 million for each of the three and six month periods ended September 30, 2013. These items also resulted in corresponding adjustments to the investments in subsidiaries on the balance sheet as of September 30, 2013 and adjustments to net income (loss) and equity in income of subsidiaries in the statement of cash flows, although net cash provided by operating activities for the six months ended September 30, 2013 remained unchanged. Revisions were also made to increase the cumulative translation adjustment of the Issuer and subsidiary guarantors by approximately $1.0 million each, with corresponding adjustments to the investment in subsidiaries and stockholders' equity balances.
	The Company assessed the materiality of these items on the previously issued interim financial statements in accordance with SEC Staff Accounting Bulletin No. 99 and No. 108, and concluded that the revisions were not material to the consolidated financial statements. The Company disclosed the impact of the revisions on previously reported amounts and accordingly revised the Condensed Consolidating Financial Statements relating to the second quarter of fiscal 2014. There were no changes to any of the Company's Consolidated Financial Statements.
	Condensed Consolidating Statements of Income and Comprehensive Income
	Three Months Ended December 31, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	27,937		$	155,733		$	14,273		$	(1,508	)	$	196,435
	Other revenues	—			83			1,166			266			(344		)	1,171
	Total revenues	—			28,020			156,899			14,539			(1,852		)	197,606
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			10,296			71,891			5,208			(1,534		)	85,861
	Gross profit	—			17,724			85,008			9,331			(318		)	111,745
	Operating Expenses
	Advertising and promotion	—			2,175			25,202			2,767			—			30,144
	General and administrative	1,408			1,879			13,760			2,407			—			19,454
	Depreciation and amortization	869			156			3,864			265			—			5,154
	Total operating expenses	2,277			4,210			42,826			5,439			—			54,752
	Operating income (loss)	(2,277		)	13,514			42,182			3,892			(318		)	56,993
	Other (income) expense
	Interest income	(12,226		)	(21,602		)	(1,278		)	(15		)	35,101			(20		)
	Interest expense	8,611			24,612			25,212			1,278			(35,101		)	24,612
	Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
	Equity in (income) loss of subsidiaries	(20,462		)	(12,977		)	(1,654		)	—			35,093			—
	Total other (income) expense	(24,077		)	(9,967		)	21,147			1,263			35,093			23,459
	Income before income taxes	21,800			23,481			21,035			2,629			(35,411		)	33,534
	Provision (benefit) for income taxes	507			3,782			6,977			975			—			12,241
	Net income (loss)	$	21,293		$	19,699		$	14,058		$	1,654		$	(35,411	)	$	21,293
	Comprehensive income, net of tax:
	Currency translation adjustments	(8,779		)	(8,779		)	(8,779		)	(8,779		)	26,337			(8,779		)
	Total other comprehensive (loss) income	(8,779		)	(8,779		)	(8,779		)	(8,779		)	26,337			(8,779		)
	Comprehensive income (loss)	$	12,514		$	10,920		$	5,279		$	(7,125	)	$	(9,074	)	$	12,514
	Condensed Consolidating Statements of Income and Comprehensive Income
	Nine Months Ended December 31, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	80,514		$	402,967		$	40,436		$	(2,936	)	$	520,981
	Other revenues	—			308			3,506			1,104			(1,322		)	3,596
	Total revenues	—			80,822			406,473			41,540			(4,258		)	524,577
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			30,170			187,218			14,998			(3,962		)	228,424
	Gross profit	—			50,652			219,255			26,542			(296		)	296,153
	Operating Expenses
	Advertising and promotion	—			7,563			58,579			8,142			—			74,284
	General and administrative	3,662			7,793			43,079			9,054			—			63,588
	Depreciation and amortization	2,381			446			8,682			458			—			11,967
	Total operating expenses	6,043			15,802			110,340			17,654			—			149,839
	Operating income (loss)	(6,043		)	34,850			108,915			8,888			(296		)	146,314
	Other (income) expense
	Interest income	(36,604		)	(52,546		)	(3,800		)	(55		)	92,938			(67		)
Interest expense	25,788			57,505			63,350			3,800			(92,938		)	57,505
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Equity in (income) loss of subsidiaries	(53,718		)	(33,700		)	(2,565		)	—			89,983			—
Total other (income) expense	(64,534		)	(28,741		)	55,852			3,745			89,983			56,305
Income before income taxes	58,491			63,591			53,063			5,143			(90,279		)	90,009
Provision for income taxes	4,003			10,761			18,179			2,578			—			35,521
Net income (loss)	$	54,488		$	52,830		$	34,884		$	2,565		$	(90,279	)	$	54,488
Comprehensive income, net of tax:
Currency translation adjustments	(16,883		)	(16,883		)	(16,883		)	(16,883		)	50,649			(16,883		)
Total other comprehensive (loss) income	(16,883		)	(16,883		)	(16,883		)	(16,883		)	50,649			(16,883		)
Comprehensive income (loss)	$	37,605		$	35,947		$	18,001		$	(14,318	)	$	(39,630	)	$	37,605
Condensed Consolidating Statements of Income and Comprehensive Income
Three Months Ended December 31, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	25,371		$	112,662		$	7,502		$	(1,822	)	$	143,713
Other revenues	—			75			1,160			10			(87		)	1,158
Total revenues	—			25,446			113,822			7,512			(1,909		)	144,871
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,361			53,750			2,325			(1,033		)	64,403
Gross profit	—			16,085			60,072			5,187			(876		)	80,468
Operating Expenses
Advertising and promotion	—			1,748			20,336			2,145			—			24,229
General and administrative	165			2,132			8,967			873			—			12,137
Depreciation and amortization	983			149			2,440			72			—			3,644
Total operating expenses	1,148			4,029			31,743			3,090			—			40,010
Operating income (loss)	(1,148		)	12,056			28,329			2,097			(876		)	40,458
Other (income) expense
Interest income	(12,305		)	(14,437		)	(731		)	(6		)	27,463			(16		)
Interest expense	8,671			21,276			18,061			731			(27,463		)	21,276
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(1,148		)	(6,845		)	(999		)	—			8,992			—
Total other (income) expense	(4,782		)	15,006			16,331			725			8,992			36,272
Income (loss) before income taxes	3,634			(2,950		)	11,998			1,372			(9,868		)	4,186
Provision for income taxes	504			(2,541		)	2,720			373			—			1,056
Net income (loss)	$	3,130		$	(409	)	$	9,278		$	999		$	(9,868	)	$	3,130
Comprehensive income, net of tax:
Currency translation adjustments	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Total other comprehensive income (loss)	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Comprehensive income (loss)	$	436		$	(3,103	)	$	6,584		$	(1,695	)	$	(1,786	)	$	436
Condensed Consolidating Statements of Income and Comprehensive Income
Nine Months Ended December 31, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	74,757		$	361,753		$	16,174		$	(1,822	)	$	450,862
Other revenues	—			210			3,454			1,112			(1,310		)	3,466
Total revenues	—			74,967			365,207			17,286			(3,132		)	454,328
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			28,157			165,252			6,461			(2,256		)	197,614
Gross profit	—			46,810			199,955			10,825			(876		)	256,714
Operating Expenses
Advertising and promotion	—			8,672			55,036			3,749			—			67,457
General and administrative	2,555			5,256			25,782			1,797			—			35,390
Depreciation and amortization	2,017			434			7,625			130			—			10,206
Total operating expenses	4,572			14,362			88,443			5,676			—			113,053
Operating income (loss)	(4,572		)	32,448			111,512			5,149			(876		)	143,661
Other (income) expense
Interest income	(37,296		)	(42,765		)	(1,441		)	(30		)	81,488			(44		)
Interest expense	25,965			53,648			54,082			1,441			(81,488		)	53,648
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Total other (income) expense	(62,678		)	(16,102		)	49,774			1,411			96,211			68,616
Income (loss) before income taxes	58,106			48,550			61,738			3,738			(97,087		)	75,045
Provision for income taxes	1,492			1,609			14,459			871			—			18,431
Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614
Comprehensive income, net of tax:
Currency translation adjustments	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Total other comprehensive income (loss)	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Comprehensive income (loss)	$	55,043		$	45,370		$	45,708		$	1,296		$	(92,374	)	$	55,043
Condensed Consolidating Balance Sheet
December 31, 2014
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Assets
Current assets
Cash and cash equivalents	$	14,275		$	—		$	489		$	7,187		$	—		$	21,951
Accounts receivable, net	7			14,376			65,113			8,196			—			87,692
Inventories	—			8,976			61,169			6,403			(1,308		)	75,240
Deferred income tax assets	329			759			6,762			496			—			8,346
Prepaid expenses and other current assets	2,183			253			4,365			732			—			7,533
Total current assets	16,794			24,364			137,898			23,014			(1,308		)	200,762
Property and equipment, net	9,752			187			1,970			1,180			—			13,089
Goodwill	—			66,007			204,205			21,680			—			291,892
Intangible assets, net	—			192,459			1,858,708			92,917			—			2,144,084
Other long-term assets	—			30,769			—			—			—			30,769
Intercompany receivables	1,208,881			2,642,233			869,979			9,417			(4,730,510		)	—
Investment in subsidiary	1,529,929			1,217,930			73,633			—			(2,821,492		)	—
Total Assets	$	2,765,356		$	4,173,949		$	3,146,393		$	148,208		$	(7,553,310	)	$	2,680,596
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	1,956		$	5,006		$	27,884		$	3,721		$	—		$	38,567
Accrued interest payable	—			11,792			—						—			11,792
Other accrued liabilities	8,738			2,343			25,494			4,100			—			40,675
Total current liabilities	10,694			19,141			53,378			7,821			—			91,034
Long-term debt
Principal amount	—			1,643,600			—			—			—			1,643,600
Less unamortized discount	—			(5,639		)	—			—			—			(5,639		)
Long-term debt, net of unamortized discount	—			1,637,961			—			—			—			1,637,961
Deferred income tax liabilities	—			58,475			283,874			36			—			342,385
Other long-term liabilities	—			—			—			279			—			279
Intercompany payables	2,145,725			998,359			1,518,457			67,969			(4,730,510		)	—
Total Liabilities	2,156,419			2,713,936			1,855,709			76,105			(4,730,510		)	2,071,659
Stockholders' Equity
Common stock	525			—			—			—			—			525
Additional paid-in capital	423,985			1,280,948			1,131,578			74,031			(2,486,557		)	423,985
Treasury stock, at cost - 255 shares	(3,062		)	—			—			—			—			(3,062		)
Accumulated other comprehensive (loss) income, net of tax	(16,144		)	(16,144		)	(16,144		)	(16,144		)	48,432			(16,144		)
Retained earnings (accumulated deficit)	203,633			195,209			175,250			14,216			(384,675		)	203,633
Total Stockholders' Equity	608,937			1,460,013			1,290,684			72,103			(2,822,800		)	608,937
Total Liabilities and Stockholders' Equity	$	2,765,356		$	4,173,949		$	3,146,393		$	148,208		$	(7,553,310	)	$	2,680,596
Condensed Consolidating Balance Sheet
March 31, 2014
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Assets
Current assets
Cash and cash equivalents	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331
Accounts receivable, net	473			14,245			45,885			4,447			—			65,050
Inventories	—			14,357			46,309			5,930			(1,010		)	65,586
Deferred income tax assets	260			925			4,914			445			—			6,544
Prepaid expenses and other current assets	8,004			113			2,898			659			—			11,674
Total current assets	33,381			29,640			100,006			15,168			(1,010		)	177,185
Property and equipment, net	8,966			112			226			293			—			9,597
Goodwill	—			66,007			101,540			23,364			—			190,911
Intangible assets, net	—			192,861			1,169,943			32,013			—			1,394,817
Other long-term assets	—			23,153			—			—			—			23,153
Intercompany receivable	655,146			1,824,482			656,759			13,595			(3,149,982		)	—
Investment in subsidiary	1,497,357			749,947			34,562			—			(2,281,866		)	—
Total Assets	$	2,194,850		$	2,886,202		$	2,063,036		$	84,433		$	(5,432,858	)	$	1,795,663
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553		$	2,659		$	—		$	48,286
Accrued interest payable	—			9,626			—			—			—			9,626
Other accrued liabilities	7,728			2,117			13,443			3,158			—			26,446
Total current liabilities	12,144			19,401			46,996			5,817			—			84,358
Long-term debt
Principal amount	—			937,500			—			—			—			937,500
Less unamortized discount	—			(3,086		)	—			—			—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—			—			—			934,414
Deferred income tax liabilities	—			56,827			156,327			50			—			213,204
Other long-term liabilities	—			—			—			327			—			327
Intercompany payable	1,619,346			451,497			1,037,105			42,034			(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428			48,228			(3,149,982		)	1,232,303
Stockholders' Equity
Common stock	520			—			—			—			—			520
Additional paid-in capital	414,387			1,280,945			681,503			23,815			(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—			—			—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739			739			(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366			11,651			(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608			36,205			(2,282,876		)	563,360
Total Liabilities and Stockholders' Equity	$	2,194,850		$	2,886,202		$	2,063,036		$	84,433		$	(5,432,858	)	$	1,795,663
Condensed Consolidating Statement of Cash Flows
Nine Months Ended December 31, 2014
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Operating Activities
Net income (loss)	$	54,488		$	52,830		$	34,884		$	2,565		$	(90,279	)	$	54,488
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	2,381			446			8,682			458			—			11,967
Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
Deferred income taxes	(69		)	1,814			17,900			(128		)	—			19,517
Amortization of deferred financing costs	—			4,568			—			—			—			4,568
Stock-based compensation costs	4,919			—			—			—			—			4,919
Amortization of debt discount	—			1,336			—			—			—			1,336
Lease termination costs	—			—			1,125			—			—			1,125
Loss (gain) on sale or disposal of equipment	—			—			—			321			—			321
Equity in income of subsidiaries	(53,718		)	(33,700		)	(2,565		)	—			89,983			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	466			(131		)	6,556			(4,778		)	—			2,113
Inventories	—			5,381			8,109			692			296			14,478
Prepaid expenses and other current assets	5,821			(140		)	2,070			(153		)	—			7,598
Accounts payable	(2,460		)	(2,652		)	(21,748		)	1,408			—			(25,452		)
Accrued liabilities	1,010			2,392			2,978			1,917			—			8,297
Net cash provided by operating activities	12,838			32,144			56,858			2,302			—			104,142
Investing Activities
Purchases of property and equipment	(3,167		)	—			(419		)	(114		)	—			(3,700		)
Proceeds from sale of business	—			—			18,500			—			—			18,500
Proceeds from sale of asset	—			—			10,000			—			—			10,000
Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)	—			—			(749,666		)
Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
Intercompany activity, net	—			(809,157		)	731,166			77,991			—			—
Net cash (used in) provided by investing activities	(3,167		)	(809,157		)	9,581			(114		)	—			(802,857		)
Financing Activities
Term loan borrowings	—			720,000			—			—			—			720,000
Term loan repayments	—			(80,000		)	—			—			—			(80,000		)
Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
Payment of deferred financing costs	—			(16,072		)	—			—			—			(16,072		)
Proceeds from exercise of stock options	3,654			—			—			—			—			3,654
Proceeds from exercise of restricted stock exercises	57			—			—			—			—			57
Excess tax benefits from share-based awards	1,030			—			—			—			—			1,030
Fair value of shares surrendered as payment of tax withholding	(1,688		)	—			—			—			—			(1,688		)
Intercompany activity, net	(23,093		)	86,985			(65,950		)	2,058			—			—
Net cash provided by (used in) financing activities	(20,040		)	777,013			(65,950		)	2,058			—			693,081
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(746		)	—			(746		)
(Decrease) increase in cash and cash equivalents	(10,369		)	—			489			3,500			—			(6,380		)
Cash and cash equivalents - beginning of period	24,644			—			—			3,687			—			28,331
Cash and cash equivalents - end of period	$	14,275		$	—		$	489		$	7,187		$	—		$	21,951
Condensed Consolidating Statement of Cash Flows
Nine Months Ended December 31, 2013
(In thousands)	Prestige Brands Holdings, Inc.			Prestige			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
				Brands,
				Inc.,
				the issuer
Operating Activities
Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	2,017			434			7,624			134			—			10,209
Deferred income taxes	(33		)	(37		)	10,336			(5		)	—			10,261
Amortization of deferred financing costs	—			6,023			—			—			—			6,023
Stock-based compensation costs	3,763			—			—			—			—			3,763
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Premium payment on 2010 Senior Notes Tendered	—			(12,768		)	—			—			—			(12,768		)
Amortization of debt discount	—			3,115			—			—			—			3,115
Loss (gain) on sale or disposal of equipment	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(106		)	(474		)	10,714			(1,639		)	—			8,495
Inventories	—			(3,496		)	2,454			(2,096		)	876			(2,262		)
Prepaid expenses and other current assets	(3,206		)	27			296			100			—			(2,783		)
Accounts payable	462			1,041			(3,375		)	587			—			(1,285		)
Accrued liabilities	(6,550		)	(1,498		)	(5,858		)	375			—			(13,531		)
Net cash provided by operating activities	1,614			12,323			66,600			323			—			80,860
Investing Activities
Purchases of property and equipment	(2,555		)	—			—			(103		)	—			(2,658		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash (used in) provided by investing activities	(2,555		)	(55,215		)	3			(103		)	—			(57,870		)
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	—			400,000			—			—			—			400,000
Repayment of 2010 Senior Notes	—			(201,710		)	—			—			—			(201,710		)
Term loan repayments	—			(147,500		)	—			—			—			(147,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Repayments under revolving credit agreement	—			(45,500		)	—			—			—			(45,500		)
Payment of deferred financing costs	—			(6,933		)	—			—			—			(6,933		)
Proceeds from exercise of stock options	5,738			—			—			—			—			5,738
Excess tax benefits from share-based awards	1,725			—			—			—			—			1,725
Fair value of shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	69,683			(5,465		)	(66,603		)	2,385			—			—
Net cash provided by (used in) financing activities	76,868			42,892			(66,603		)	2,385			—			55,542
Effect of exchange rate changes on cash and cash equivalents	—			—			—			151			—			151
Increase in cash and cash equivalents	75,927			—			—			2,756			—			78,683
Cash and cash equivalents - beginning of period	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of period	$	90,647		$	—		$	—		$	3,706		$	—		$	94,353

Business_and_Basis_of_Presenta1

Business and Basis of Presentation (Policies)	9 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation
	The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  All significant intercompany transactions and balances have been eliminated in the Consolidated Financial Statements.  In the opinion of management, the Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented.  Our fiscal year ends on March 31st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2015”) mean our fiscal year ending or ended on March 31st of that year. Operating results for the three and nine months ended December 31, 2014 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2015.  These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2014.
Revision	Revision
	We revised the classification of certain promotional expenses that were incurred in the prior year to correctly present the amounts as a reduction to net sales. The amounts were not material to any of the periods presented.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from these estimates.  As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
Cash and Cash Equivalents	Cash and Cash Equivalents
	We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents.  Substantially all of our cash is held by a large regional bank with headquarters in California.  We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.
Accounts Receivable	Accounts Receivable
	We extend non-interest-bearing trade credit to our customers in the ordinary course of business.  We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable.  In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
Inventories	Inventories
	Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method.  We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value.  Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:
		Years
	Machinery	5
	Computer equipment and software	3
	Furniture and fixtures	7
	Leasehold improvements	*
	* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.
	Expenditures for maintenance and repairs are charged to expense as incurred.  When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income.
	Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Goodwill	Goodwill
	The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in purchase business combinations is classified as goodwill.  Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  Goodwill is tested for impairment at the reporting unit “brand” level, which is one level below the operating segment level.
Intangible Assets	Intangible Assets
	Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization.  For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives ranging from 3 to 30 years and these assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable.  An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired.  If the carrying amount of the asset exceeds its fair value, an impairment loss is recognized.
Deferred Financing Costs	Deferred Financing Costs
	We have incurred debt origination costs in connection with the issuance of long-term debt.  These costs are capitalized as deferred financing costs and amortized using the effective interest method over the term of the related debt.
Revenue Recognition	Revenue Recognition
	Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured.  We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time.  Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.
	As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products.  The cost of these promotional programs varies based on the actual number of units sold during a finite period of time.  These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising.  Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered.  At the completion of a promotional program, the estimated amounts are adjusted to actual results.
	Due to the nature of the consumer products industry, we are required to estimate future product returns.  Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
Cost of Sales	Cost of Sales
	Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.
Advertising and Promotion Costs	Advertising and Promotion Costs
	Advertising and promotion costs are expensed as incurred.  Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales.  Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
Stock-based Compensation	Stock-based Compensation
	We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award.  Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.
Income Taxes	Income Taxes
	Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.  A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our uncertainties.
	We are subject to taxation in the United States and various state and foreign jurisdictions.
	We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
Earnings Per Share	Earnings Per Share
	Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period.  Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period.  Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.
Recently Issued Accounting Standards	Recently Issued Accounting Standards
	In January 2015, the FASB issued Accounting Standards Update ("ASU") 2015-01. The amendments in this update eliminate the concept of extraordinary items in Subtopic 225-20, which required entities to consider whether an underlying event or transaction is extraordinary. However, the amendments retain the presentation and disclosure guidance for items that are unusual in nature or occur infrequently. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of ASU 2015-01 is not expected to have a material impact on our Consolidated Financial Statements.
	In November 2014, the FASB issued ASU 2014-17, Pushdown Accounting, which clarifies whether and at what threshold an acquired entity that is a business or nonprofit activity can apply pushdown accounting in its separate financial statements. This ASU provides companies with the option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. The election to apply pushdown accounting can be made either in the period in which the change of control occurred, or in a subsequent period. The amendments in this update were effective November 18, 2014. The adoption of ASU 2014-17 did not have a material impact on our Consolidated Financial Statements.
	In November 2014, the FASB issued ASU 2014-16, Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity. The amendments in this update clarify how current GAAP should be interpreted in evaluating economic characteristics and risks and ultimately determining whether the host contract in a hybrid financial instrument that is issued in the form of a share is more akin to debt or to equity. The effects of initially adopting the amendments in this update should be applied on a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of the fiscal year for which the amendments are effective. The amendments in this update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2014-16 is not expected to have a material impact on our Consolidated Financial Statements.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period beginning after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements.
	In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The amendments in this update are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are evaluating the impact of adopting this prospective guidance on our consolidated results of operations and financial condition.
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 is not expected to have a material impact on our Consolidated Financial Statements.
	Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Business_and_Basis_of_Presenta2

Business and Basis of Presentation (Tables)	9 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Property and Equipment	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:
		Years
	Machinery	5
	Computer equipment and software	3
	Furniture and fixtures	7
	Leasehold improvements	*
	* Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Dec. 31, 2014
Insight Pharmaceuticals
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date.
	(In thousands)	3-Sep-14
	Cash acquired	$	3,507
	Accounts receivable	25,784
	Inventories	23,559
	Deferred income tax assets - current	860
	Prepaids and other current assets	1,407
	Property, plant and equipment	2,308
	Goodwill	103,255
	Intangible assets	724,374
	Total assets acquired	885,054
	Accounts payable	16,079
	Accrued expenses	8,003
	Deferred income tax liabilities - long term	107,799
	Total liabilities assumed	131,881
	Total purchase price	$	753,173
Schedule of Pro Forma Information	The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results.
	(In thousands, except per share data)		Nine Months Ended December 31, 2014
	Revenues		$	593,171
	Net income		$	62,688
	Earnings per share:
	Basic		$	1.2
	Diluted		$	1.19
	(In thousands, except per share data)		Nine Months Ended December 31, 2013
	Revenues		$	579,762
	Net income		$	57,537
	Earnings per share:
	Basic		$	1.12
	Diluted		$	1.1
Hydralyte
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date.
	(In thousands)	30-Apr-14
	Inventories	$	1,970
	Property, plant and equipment, net	1,267
	Goodwill	1,224
	Intangible assets, net	73,580
	Total assets acquired	78,041
	Accrued expenses	38
	Other long term liabilities	12
	Total liabilities assumed	50
	Net assets acquired	$	77,991
Care Pharma
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes our allocation of the assets acquired and liabilities assumed as of the July 1, 2013 acquisition date.
	(In thousands)	1-Jul-13
	Cash acquired	$	1,546
	Accounts receivable	1,658
	Inventories	2,465
	Deferred income taxes	283
	Prepaids and other current assets	647
	Property, plant and equipment	163
	Goodwill	23,122
	Intangible assets	31,502
	Total assets acquired	61,386
	Accounts payable	1,537
	Accrued expenses	2,788
	Other long term liabilities	300
	Total liabilities assumed	4,625
	Net assets acquired	$	56,761

Accounts_Receivable_Tables

Accounts Receivable (Tables)	9 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Accounts Receivable	Accounts receivable consist of the following:
	(In thousands)	December 31,			March 31,
		2014			2014
	Components of Accounts Receivable
	Trade accounts receivable	$	95,596		$	73,632
	Other receivables	2,998			1,360
		98,594			74,992
	Less allowances for discounts, returns and uncollectible accounts	(10,902		)	(9,942		)
	Accounts receivable, net	$	87,692		$	65,050

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following:
	(In thousands)	December 31,		March 31,
		2014		2014
	Components of Inventories
	Packaging and raw materials	$	6,909	$	3,099
	Finished goods	68,331		62,487
	Inventories	$	75,240	$	65,586

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment consist of the following:
	(In thousands)	December 31,			March 31,
		2014			2014
	Components of Property and Equipment
	Machinery	$	4,313		$	1,927
	Computer equipment and software	9,950			8,923
	Furniture and fixtures	2,427			1,858
	Leasehold improvements	6,705			4,734
		23,395			17,442
	Accumulated depreciation	(10,306		)	(7,845		)
	Property and equipment, net	$	13,089		$	9,597

Goodwill_Tables

Goodwill (Tables)	9 Months Ended
	Dec. 31, 2014
Goodwill [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by reportable segment is as follows:
	(In thousands)	North American OTC		International OTC			Household			Consolidated
		Healthcare		Healthcare			Cleaning
	Balance — March 31, 2014	$	160,157	$	23,365		$	7,389		$	190,911
	Additions	103,254		1,224			—			104,478
	Reductions	—		—			(589		)	(589		)
	Effects of foreign currency exchange rates	—		(2,908		)	—			(2,908		)
	Balance — December 31, 2014	$	263,411	$	21,681		$	6,800		$	291,892

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Dec. 31, 2014
Intangible Assets [Abstract]
Reconciliation of the Activity Affecting Intangible Assets	A reconciliation of the activity affecting intangible assets is as follows:
	(In thousands)	Indefinite			Finite Lived			Totals
		Lived			Trademarks
		Trademarks
	Gross Carrying Amounts
	Balance — March 31, 2014	$	1,273,878		$	204,740		$	1,478,618
	Additions	673,180			124,774			797,954
	Reductions	(9,548		)	(17,674		)	(27,222		)
	Effects of foreign currency exchange rates	(12,371		)	(197		)	(12,568		)
	Balance — December 31, 2014	1,925,139			311,643			2,236,782
	Accumulated Amortization
	Balance — March 31, 2014	—			83,801			83,801
	Additions	—			8,915			8,915
	Effects of foreign currency exchange rates	—			(18		)	(18		)
	Balance — December 31, 2014	—			92,698			92,698
	Intangible assets, net - December 31, 2014	$	1,925,139		$	218,945		$	2,144,084
	Intangible Assets, net by Reportable Segment:
	North American OTC Healthcare	$	1,723,498		$	192,756		$	1,916,254
	International OTC Healthcare	91,369			1,330			92,699
	Household Cleaning	110,272			24,859			135,131
	Intangible assets, net - December 31, 2014	$	1,925,139		$	218,945		$	2,144,084
Schedule of Expected Amortization Expense	At December 31, 2014, finite-lived intangible assets are being amortized over a period of 3 to 30 years, and the associated amortization expense is expected to be as follows:
	(In thousands)
	Year Ending March 31,		Amount
	2015 (Remaining three months ending March 31, 2015)		$	3,887
	2016		15,547
	2017		15,547
	2018		15,547
	2019		15,547
	Thereafter		152,870
			$	218,945

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	9 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following:
	(In thousands)	December 31,		March 31,
		2014		2014
	Accrued marketing costs	$	19,413	$	11,812
	Accrued compensation costs	6,455		6,232
	Accrued broker commissions	1,484		1,019
	Income taxes payable	2,163		1,854
	Accrued professional fees	2,999		2,002
	Deferred rent	1,060		1,258
	Accrued production costs	4,390		1,506
	Accrued lease termination costs	1,110		—
	Other accrued liabilities	1,601		763
		$	40,675	$	26,446

LongTerm_Debt_Tables

Long-Term Debt (Tables)	9 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated:
	(In thousands, except percentages)	December 31,			March 31,
		2014			2014
	2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021.	$	400,000		$	400,000
	2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020.	250,000			250,000
	2012 Term B-1 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on January 31, 2019.	247,500			287,500
	2012 Term B-2 Loan bearing interest at the Borrower's option at either a base rate with a floor of 2.00% plus applicable margin or LIBOR with a floor of 1.00% plus applicable margin, due on September 3, 2021.	680,000			—
	2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on January 31, 2017.	66,100			—
		1,643,600			937,500
	Current portion of long-term debt	—			—
		1,643,600			937,500
	Less: unamortized discount	(5,639		)	(3,086		)
	Long-term debt, net of unamortized discount	$	1,637,961		$	934,414
Aggregate Future Principal Payments	As of December 31, 2014, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows:
	(In thousands)
	Year Ending March 31,	Amount
	2015 (remaining three months ending March 31, 2015)	$	—
	2016	—
	2017	66,100
	2018	—
	2019	247,500
	Thereafter	1,330,000
		$	1,643,600

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive (Loss) Income (Tables)	9 Months Ended
	Dec. 31, 2014
Accumulated Other Comprehensive Income [Abstract]
Schedule of Accumulated Other Comprehensive Income	The table below presents accumulated other comprehensive (loss) income (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners.
	AOCI consisted of the following at December 31, 2014 and March 31, 2014:
		December 31,			March 31,
	(In thousands)	2014			2014
	Components of Accumulated Other Comprehensive (Loss) Income
	Cumulative translation adjustment	$	(16,144	)	$	739
	Total accumulated other comprehensive (loss) income, net of tax	$	(16,144	)	$	739

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share:
		Three Months Ended December 31,				Nine Months Ended December 31,
	(In thousands, except per share data)	2014		2013		2014		2013
	Numerator
	Net income	$	21,293	$	3,130	$	54,488	$	56,614
	Denominator
	Denominator for basic earnings per share — weighted average shares outstanding	52,278		51,806		52,110		51,498
	Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	452		639		512		738
	Denominator for diluted earnings per share	52,730		52,445		52,622		52,236
	Earnings per Common Share:
	Basic net earnings per share	$	0.41	$	0.06	$	1.05	$	1.1
	Diluted net earnings per share	$	0.4	$	0.06	$	1.04	$	1.08

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Restricted Shares	A summary of the Company's restricted shares granted under the Plan is presented below:
					Weighted-
		Shares			Average
		(in thousands)			Grant-Date
	Restricted Shares				Fair Value
	Nine months ended December 31, 2013
	Vested and nonvested at March 31, 2013	421.3			$	11.01
	Granted	126.6			30.19
	Vested and issued	(59.7	)		8.42
	Forfeited	(5.6	)		15.11
	Vested and nonvested at December 31, 2013	482.6			16.32
	Vested at December 31, 2013	83.1			9.63
	Nine months ended December 31, 2014:
	Vested and nonvested at March 31, 2014	437.5			$	16.76
	Granted	104.4			33.3
	Vested and issued	(122.8	)		13.62
	Forfeited	(21.3	)		20.77
	Vested and nonvested at December 31, 2014	397.8			21.86
	Vested at December 31, 2014	76.6			11.62
Stock Options, Valuation Assumptions
		Nine Months Ended December 31,
		2014				2013
	Expected volatility	47.3		%		48		%
	Expected dividends	$	—			$	—
	Expected term in years	6				6
	Risk-free rate	2.2		%		1.3		%
Stock Option Activity	A summary of option activity under the Plan is as follows:
					Weighted-				Weighted-	Aggregate
					Average				Average	Intrinsic
		Shares			Exercise				Remaining	Value
		(in thousands)			Price				Contractual	(in thousands)
	Options								Term
	Nine months ended December 31, 2013:
	Outstanding at March 31, 2013	1,386.40			$	10.43
	Granted	227.7			29.94
	Exercised	(589.9	)		9.73
	Forfeited or expired	(14.2	)		14.56
	Outstanding at December 31, 2013	1,010.00			15.18				7.6	$	20,828
	Exercisable at December 31, 2013	172.1			11.34				6.8	4,210
	Nine months ended December 31, 2014:
	Outstanding at March 31, 2014	994.9			$	15.24
	Granted	307.5			33.5
	Exercised	(363.4	)		10.05
	Forfeited or expired	(47.5	)		25.76
	Outstanding at December 31, 2014	891.5			23.09				7.9	$	10,368
	Exercisable at December 31, 2014	335.1			15.01				6.7	6,604

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The following summarizes future minimum lease payments for our operating leases as of December 31, 2014:
	(In thousands)
	Year Ending March 31,	Facilities		Equipment		Total
	2015 (Remaining three months ending March 31, 2015)	$	422	$	274	$	696
	2016	1,612		311		1,923
	2017	1,772		77		1,849
	2018	1,856		—		1,856
	2019	1,864		—		1,864
	Thereafter	2,465		—		2,465
		$	9,991	$	662	$	10,653
Unrecorded Unconditional Purchase Obligations Disclosure	Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement.
	(In thousands)
	Year Ending March 31,	Amount
	2015 (Remaining three months ending March 31, 2015)	273
	2016	1,074
	2017	1,044
	2018	1,013
	2019	982
	Thereafter	560
		$	4,946

Business_Segments_Tables

Business Segments (Tables)	9 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Information about our Operating and Reportable Segments	The tables below summarize information about our reportable segments.
		Three Months Ended December 31, 2014
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	160,655		$	17,071	$	20,218	$	197,944
	Elimination of intersegment revenues	(1,509		)	—		—		(1,509		)
	Third-party segment revenues	159,146			17,071		20,218		196,435
	Other revenues	151			4		1,016		1,171
	Total segment revenues	159,297			17,075		21,234		197,606
	Cost of sales	63,479			6,247		16,135		85,861
	Gross profit	95,818			10,828		5,099		111,745
	Advertising and promotion	26,779			2,776		589		30,144
	Contribution margin	$	69,039		$	8,052	$	4,510	81,601
	Other operating expenses								24,608
	Operating income								56,993
	Other expense								23,459
	Income before income taxes								33,534
	Provision for income taxes								12,241
	Net income								$	21,293
		Nine Months Ended December 31, 2014
	(In thousands)	North			International		Household		Consolidated
		American			OTC		Cleaning
		OTC			Healthcare
		Healthcare
	Gross segment revenues	$	409,767		$	48,093	$	66,057	$	523,917
	Elimination of intersegment revenues	(2,936		)	—		—		(2,936		)
	Third-party segment revenues	406,831			48,093		66,057		520,981
	Other revenues	478			62		3,056		3,596
	Total segment revenues	407,309			48,155		69,113		524,577
	Cost of sales	158,005			17,926		52,493		228,424
	Gross profit	249,304			30,229		16,620		296,153
	Advertising and promotion	64,573			8,151		1,560		74,284
	Contribution margin	$	184,731		$	22,078	$	15,060	221,869
	Other operating expenses								75,555
	Operating income								146,314
	Other expense								56,305
	Income before income taxes								90,009
	Provision for income taxes								35,521
	Net income								$	54,488
		Three Months Ended December 31, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	117,476		$	8,214	$	19,532	$	145,222
	Elimination of intersegment revenues	(1,509		)	—		—		(1,509		)
	Third-party segment revenues	115,967			8,214		19,532		143,713
	Other revenues	150			—		1,008		1,158
	Total segment revenues	116,117			8,214		20,540		144,871
	Cost of sales	45,886			3,144		15,373		64,403
	Gross profit	70,231			5,070		5,167		80,468
	Advertising and promotion	21,380			2,145		704		24,229
	Contribution margin	$	48,851		$	2,925	$	4,463	56,239
	Other operating expenses								15,781
	Operating income								40,458
	Other expense								36,272
	Income before income taxes								4,186
	Provision for income taxes								1,056
	Net income								$	3,130
		Nine Months Ended December 31, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Gross segment revenues	$	369,356		$	20,636	$	63,198	$	453,190
	Elimination of intersegment revenues	(2,328		)	—		—		(2,328		)
	Third-party segment revenues	367,028			20,636		63,198		450,862
	Other revenues	450			14		3,002		3,466
Total segment revenues	367,478			20,650		66,200		454,328
Cost of sales	140,419			8,947		48,248		197,614
Gross profit	227,059			11,703		17,952		256,714
Advertising and promotion	61,477			3,855		2,125		67,457
Contribution margin	$	165,582		$	7,848	$	15,827	189,257
Other operating expenses								45,596
Operating income								143,661
Other expense								68,616
Income before income taxes								75,045
Provision for income taxes								18,431
Net income								$	56,614
Information about our Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups.
		Three Months Ended December 31, 2014
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Analgesics	$	28,187		$	657	$	—	$	28,844
	Cough & Cold	31,927			3,831		—		35,758
	Women's Health	31,364			589		—		31,953
	Gastrointestinal	17,365			6,668		—		24,033
	Eye & Ear Care	19,020			4,577		—		23,597
	Dermatologicals	17,663			570		—		18,233
	Oral Care	12,300			172		—		12,472
	Other OTC	1,471			11		—		1,482
	Household Cleaning	—			—		21,234		21,234
	Total segment revenues	$	159,297		$	17,075	$	21,234	$	197,606
		Nine Months Ended December 31, 2014
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Analgesics	$	82,290		$	2,114	$	—	$	84,404
	Cough & Cold	76,741			14,090		—		90,831
	Women's Health	40,851			1,765		—		42,616
	Gastrointestinal	58,899			14,764		—		73,663
	Eye & Ear Care	61,150			13,247		—		74,397
	Dermatologicals	47,383			1,799		—		49,182
	Oral Care	35,421			361		—		35,782
	Other OTC	4,574			15		—		4,589
	Household Cleaning	—			—		69,113		69,113
	Total segment revenues	$	407,309		$	48,155	$	69,113	$	524,577
		Three Months Ended December 31, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Analgesics	$	25,117		$	648	$	—	$	25,765
	Cough & Cold	29,863			3,738		—		33,601
	Women's Health	404			619		—		1,023
	Gastrointestinal	19,420			272		—		19,692
	Eye & Ear Care	16,973			2,244		—		19,217
	Dermatologicals	11,019			497		—		11,516
	Oral Care	11,125			196		—		11,321
	Other OTC	2,196			—		—		2,196
	Household Cleaning	—			—		20,540		20,540
	Total segment revenues	$	116,117		$	8,214	$	20,540	$	144,871
		Nine Months Ended December 31, 2013
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Analgesics	$	82,596		$	1,375	$	—	$	83,971
	Cough & Cold	78,791			9,745		—		88,536
	Women's Health	1,392			1,252		—		2,644
	Gastrointestinal	62,873			583		—		63,456
	Eye & Ear Care	56,949			6,128		—		63,077
	Dermatologicals	43,366			1,194		—		44,560
	Oral Care	35,238			373		—		35,611
	Other OTC	6,273			—		—		6,273
	Household Cleaning	—			—		66,200		66,200
	Total segment revenues	$	367,478		$	20,650	$	66,200	$	454,328
Allocation of Long-Term Assets to Segments	At December 31, 2014, approximately 95.3% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.7% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows:
	(In thousands)	North American OTC			International OTC		Household		Consolidated
		Healthcare			Healthcare		Cleaning
	Goodwill	$	263,411		$	21,681	$	6,800	$	291,892
	Intangible assets
	Indefinite-lived	1,723,498			91,369		110,272		1,925,139
	Finite-lived	192,756			1,330		24,859		218,945
	Intangible assets, net	1,916,254			92,699		135,131		2,144,084
	Total	$	2,179,665		$	114,380	$	141,931	$	2,435,976

Condensed_Consolidating_Financ1

Condensed Consolidating Financial Statements (Tables)	9 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Statements of Income and Comprehensive Income	Condensed Consolidating Statements of Income and Comprehensive Income
	Three Months Ended December 31, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	27,937		$	155,733		$	14,273		$	(1,508	)	$	196,435
	Other revenues	—			83			1,166			266			(344		)	1,171
	Total revenues	—			28,020			156,899			14,539			(1,852		)	197,606
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			10,296			71,891			5,208			(1,534		)	85,861
	Gross profit	—			17,724			85,008			9,331			(318		)	111,745
	Operating Expenses
	Advertising and promotion	—			2,175			25,202			2,767			—			30,144
	General and administrative	1,408			1,879			13,760			2,407			—			19,454
	Depreciation and amortization	869			156			3,864			265			—			5,154
	Total operating expenses	2,277			4,210			42,826			5,439			—			54,752
	Operating income (loss)	(2,277		)	13,514			42,182			3,892			(318		)	56,993
	Other (income) expense
	Interest income	(12,226		)	(21,602		)	(1,278		)	(15		)	35,101			(20		)
	Interest expense	8,611			24,612			25,212			1,278			(35,101		)	24,612
	Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
	Equity in (income) loss of subsidiaries	(20,462		)	(12,977		)	(1,654		)	—			35,093			—
	Total other (income) expense	(24,077		)	(9,967		)	21,147			1,263			35,093			23,459
	Income before income taxes	21,800			23,481			21,035			2,629			(35,411		)	33,534
	Provision (benefit) for income taxes	507			3,782			6,977			975			—			12,241
	Net income (loss)	$	21,293		$	19,699		$	14,058		$	1,654		$	(35,411	)	$	21,293
	Comprehensive income, net of tax:
	Currency translation adjustments	(8,779		)	(8,779		)	(8,779		)	(8,779		)	26,337			(8,779		)
	Total other comprehensive (loss) income	(8,779		)	(8,779		)	(8,779		)	(8,779		)	26,337			(8,779		)
	Comprehensive income (loss)	$	12,514		$	10,920		$	5,279		$	(7,125	)	$	(9,074	)	$	12,514
	Condensed Consolidating Statements of Income and Comprehensive Income
	Nine Months Ended December 31, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Revenues
	Net sales	$	—		$	80,514		$	402,967		$	40,436		$	(2,936	)	$	520,981
	Other revenues	—			308			3,506			1,104			(1,322		)	3,596
	Total revenues	—			80,822			406,473			41,540			(4,258		)	524,577
	Cost of Sales
	Cost of sales (exclusive of depreciation shown below)	—			30,170			187,218			14,998			(3,962		)	228,424
	Gross profit	—			50,652			219,255			26,542			(296		)	296,153
	Operating Expenses
	Advertising and promotion	—			7,563			58,579			8,142			—			74,284
	General and administrative	3,662			7,793			43,079			9,054			—			63,588
	Depreciation and amortization	2,381			446			8,682			458			—			11,967
	Total operating expenses	6,043			15,802			110,340			17,654			—			149,839
	Operating income (loss)	(6,043		)	34,850			108,915			8,888			(296		)	146,314
	Other (income) expense
	Interest income	(36,604		)	(52,546		)	(3,800		)	(55		)	92,938			(67		)
	Interest expense	25,788			57,505			63,350			3,800			(92,938		)	57,505
	Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
	Equity in (income) loss of subsidiaries	(53,718		)	(33,700		)	(2,565		)	—			89,983			—
	Total other (income) expense	(64,534		)	(28,741		)	55,852			3,745			89,983			56,305
	Income before income taxes	58,491			63,591			53,063			5,143			(90,279		)	90,009
	Provision for income taxes	4,003			10,761			18,179			2,578			—			35,521
	Net income (loss)	$	54,488		$	52,830		$	34,884		$	2,565		$	(90,279	)	$	54,488
	Comprehensive income, net of tax:
	Currency translation adjustments	(16,883		)	(16,883		)	(16,883		)	(16,883		)	50,649			(16,883		)
	Total other comprehensive (loss) income	(16,883		)	(16,883		)	(16,883		)	(16,883		)	50,649			(16,883		)
	Comprehensive income (loss)	$	37,605		$	35,947		$	18,001		$	(14,318	)	$	(39,630	)	$	37,605
Condensed Consolidating Statements of Income and Comprehensive Income
Three Months Ended December 31, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	25,371		$	112,662		$	7,502		$	(1,822	)	$	143,713
Other revenues	—			75			1,160			10			(87		)	1,158
Total revenues	—			25,446			113,822			7,512			(1,909		)	144,871
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			9,361			53,750			2,325			(1,033		)	64,403
Gross profit	—			16,085			60,072			5,187			(876		)	80,468
Operating Expenses
Advertising and promotion	—			1,748			20,336			2,145			—			24,229
General and administrative	165			2,132			8,967			873			—			12,137
Depreciation and amortization	983			149			2,440			72			—			3,644
Total operating expenses	1,148			4,029			31,743			3,090			—			40,010
Operating income (loss)	(1,148		)	12,056			28,329			2,097			(876		)	40,458
Other (income) expense
Interest income	(12,305		)	(14,437		)	(731		)	(6		)	27,463			(16		)
Interest expense	8,671			21,276			18,061			731			(27,463		)	21,276
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(1,148		)	(6,845		)	(999		)	—			8,992			—
Total other (income) expense	(4,782		)	15,006			16,331			725			8,992			36,272
Income (loss) before income taxes	3,634			(2,950		)	11,998			1,372			(9,868		)	4,186
Provision for income taxes	504			(2,541		)	2,720			373			—			1,056
Net income (loss)	$	3,130		$	(409	)	$	9,278		$	999		$	(9,868	)	$	3,130
Comprehensive income, net of tax:
Currency translation adjustments	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Total other comprehensive income (loss)	(2,694		)	(2,694		)	(2,694		)	(2,694		)	8,082			(2,694		)
Comprehensive income (loss)	$	436		$	(3,103	)	$	6,584		$	(1,695	)	$	(1,786	)	$	436
Condensed Consolidating Statements of Income and Comprehensive Income
Nine Months Ended December 31, 2013
(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
	Brands			Brands,			Subsidiary			Non-
	Holdings,			Inc.,			Guarantors			Guarantor
	Inc.			the issuer						Subsidiaries
Revenues
Net sales	$	—		$	74,757		$	361,753		$	16,174		$	(1,822	)	$	450,862
Other revenues	—			210			3,454			1,112			(1,310		)	3,466
Total revenues	—			74,967			365,207			17,286			(3,132		)	454,328
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	—			28,157			165,252			6,461			(2,256		)	197,614
Gross profit	—			46,810			199,955			10,825			(876		)	256,714
Operating Expenses
Advertising and promotion	—			8,672			55,036			3,749			—			67,457
General and administrative	2,555			5,256			25,782			1,797			—			35,390
Depreciation and amortization	2,017			434			7,625			130			—			10,206
Total operating expenses	4,572			14,362			88,443			5,676			—			113,053
Operating income (loss)	(4,572		)	32,448			111,512			5,149			(876		)	143,661
Other (income) expense
Interest income	(37,296		)	(42,765		)	(1,441		)	(30		)	81,488			(44		)
Interest expense	25,965			53,648			54,082			1,441			(81,488		)	53,648
Loss on extinguishment of debt	—			15,012			—			—			—			15,012
Equity in (income) loss of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Total other (income) expense	(62,678		)	(16,102		)	49,774			1,411			96,211			68,616
Income (loss) before income taxes	58,106			48,550			61,738			3,738			(97,087		)	75,045
Provision for income taxes	1,492			1,609			14,459			871			—			18,431
Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614
Comprehensive income, net of tax:
Currency translation adjustments	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Total other comprehensive income (loss)	(1,571		)	(1,571		)	(1,571		)	(1,571		)	4,713			(1,571		)
Comprehensive income (loss)	$	55,043		$	45,370		$	45,708		$	1,296		$	(92,374	)	$	55,043
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet
	December 31, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Assets
	Current assets
	Cash and cash equivalents	$	14,275		$	—		$	489		$	7,187		$	—		$	21,951
	Accounts receivable, net	7			14,376			65,113			8,196			—			87,692
	Inventories	—			8,976			61,169			6,403			(1,308		)	75,240
	Deferred income tax assets	329			759			6,762			496			—			8,346
	Prepaid expenses and other current assets	2,183			253			4,365			732			—			7,533
	Total current assets	16,794			24,364			137,898			23,014			(1,308		)	200,762
	Property and equipment, net	9,752			187			1,970			1,180			—			13,089
	Goodwill	—			66,007			204,205			21,680			—			291,892
	Intangible assets, net	—			192,459			1,858,708			92,917			—			2,144,084
	Other long-term assets	—			30,769			—			—			—			30,769
	Intercompany receivables	1,208,881			2,642,233			869,979			9,417			(4,730,510		)	—
	Investment in subsidiary	1,529,929			1,217,930			73,633			—			(2,821,492		)	—
	Total Assets	$	2,765,356		$	4,173,949		$	3,146,393		$	148,208		$	(7,553,310	)	$	2,680,596
	Liabilities and Stockholders' Equity
	Current liabilities
	Accounts payable	$	1,956		$	5,006		$	27,884		$	3,721		$	—		$	38,567
	Accrued interest payable	—			11,792			—						—			11,792
	Other accrued liabilities	8,738			2,343			25,494			4,100			—			40,675
	Total current liabilities	10,694			19,141			53,378			7,821			—			91,034
	Long-term debt
	Principal amount	—			1,643,600			—			—			—			1,643,600
	Less unamortized discount	—			(5,639		)	—			—			—			(5,639		)
	Long-term debt, net of unamortized discount	—			1,637,961			—			—			—			1,637,961
	Deferred income tax liabilities	—			58,475			283,874			36			—			342,385
	Other long-term liabilities	—			—			—			279			—			279
	Intercompany payables	2,145,725			998,359			1,518,457			67,969			(4,730,510		)	—
	Total Liabilities	2,156,419			2,713,936			1,855,709			76,105			(4,730,510		)	2,071,659
	Stockholders' Equity
	Common stock	525			—			—			—			—			525
	Additional paid-in capital	423,985			1,280,948			1,131,578			74,031			(2,486,557		)	423,985
	Treasury stock, at cost - 255 shares	(3,062		)	—			—			—			—			(3,062		)
	Accumulated other comprehensive (loss) income, net of tax	(16,144		)	(16,144		)	(16,144		)	(16,144		)	48,432			(16,144		)
	Retained earnings (accumulated deficit)	203,633			195,209			175,250			14,216			(384,675		)	203,633
	Total Stockholders' Equity	608,937			1,460,013			1,290,684			72,103			(2,822,800		)	608,937
	Total Liabilities and Stockholders' Equity	$	2,765,356		$	4,173,949		$	3,146,393		$	148,208		$	(7,553,310	)	$	2,680,596
	Condensed Consolidating Balance Sheet
	March 31, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Assets
	Current assets
	Cash and cash equivalents	$	24,644		$	—		$	—		$	3,687		$	—		$	28,331
	Accounts receivable, net	473			14,245			45,885			4,447			—			65,050
	Inventories	—			14,357			46,309			5,930			(1,010		)	65,586
	Deferred income tax assets	260			925			4,914			445			—			6,544
	Prepaid expenses and other current assets	8,004			113			2,898			659			—			11,674
	Total current assets	33,381			29,640			100,006			15,168			(1,010		)	177,185
	Property and equipment, net	8,966			112			226			293			—			9,597
	Goodwill	—			66,007			101,540			23,364			—			190,911
	Intangible assets, net	—			192,861			1,169,943			32,013			—			1,394,817
	Other long-term assets	—			23,153			—			—			—			23,153
	Intercompany receivable	655,146			1,824,482			656,759			13,595			(3,149,982		)	—
	Investment in subsidiary	1,497,357			749,947			34,562			—			(2,281,866		)	—
	Total Assets	$	2,194,850		$	2,886,202		$	2,063,036		$	84,433		$	(5,432,858	)	$	1,795,663
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$	4,416		$	7,658		$	33,553		$	2,659		$	—		$	48,286
Accrued interest payable	—			9,626			—			—			—			9,626
Other accrued liabilities	7,728			2,117			13,443			3,158			—			26,446
Total current liabilities	12,144			19,401			46,996			5,817			—			84,358
Long-term debt
Principal amount	—			937,500			—			—			—			937,500
Less unamortized discount	—			(3,086		)	—			—			—			(3,086		)
Long-term debt, net of unamortized discount	—			934,414			—			—			—			934,414
Deferred income tax liabilities	—			56,827			156,327			50			—			213,204
Other long-term liabilities	—			—			—			327			—			327
Intercompany payable	1,619,346			451,497			1,037,105			42,034			(3,149,982		)	—
Total Liabilities	1,631,490			1,462,139			1,240,428			48,228			(3,149,982		)	1,232,303
Stockholders' Equity
Common stock	520			—			—			—			—			520
Additional paid-in capital	414,387			1,280,945			681,503			23,815			(1,986,263		)	414,387
Treasury stock, at cost - 206 shares	(1,431		)	—			—			—			—			(1,431		)
Accumulated other comprehensive income (loss), net of tax	739			739			739			739			(2,217		)	739
Retained earnings (accumulated deficit)	149,145			142,379			140,366			11,651			(294,396		)	149,145
Total Stockholders' Equity	563,360			1,424,063			822,608			36,205			(2,282,876		)	563,360
Total Liabilities and Stockholders' Equity	$	2,194,850		$	2,886,202		$	2,063,036		$	84,433		$	(5,432,858	)	$	1,795,663
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows
	Nine Months Ended December 31, 2014
	(In thousands)	Prestige			Prestige			Combined			Combined			Eliminations			Consolidated
		Brands			Brands,			Subsidiary			Non-
		Holdings,			Inc.,			Guarantors			Guarantor
		Inc.			the issuer						Subsidiaries
	Operating Activities
	Net income (loss)	$	54,488		$	52,830		$	34,884		$	2,565		$	(90,279	)	$	54,488
	Adjustments to reconcile net income (loss) to net cash provided by operating activities:
	Depreciation and amortization	2,381			446			8,682			458			—			11,967
	Gain on sale of asset	—			—			(1,133		)	—			—			(1,133		)
	Deferred income taxes	(69		)	1,814			17,900			(128		)	—			19,517
	Amortization of deferred financing costs	—			4,568			—			—			—			4,568
	Stock-based compensation costs	4,919			—			—			—			—			4,919
	Amortization of debt discount	—			1,336			—			—			—			1,336
	Lease termination costs	—			—			1,125			—			—			1,125
	Loss (gain) on sale or disposal of equipment	—			—			—			321			—			321
	Equity in income of subsidiaries	(53,718		)	(33,700		)	(2,565		)	—			89,983			—
	Changes in operating assets and liabilities, net of effects from acquisitions:
	Accounts receivable	466			(131		)	6,556			(4,778		)	—			2,113
	Inventories	—			5,381			8,109			692			296			14,478
	Prepaid expenses and other current assets	5,821			(140		)	2,070			(153		)	—			7,598
	Accounts payable	(2,460		)	(2,652		)	(21,748		)	1,408			—			(25,452		)
	Accrued liabilities	1,010			2,392			2,978			1,917			—			8,297
	Net cash provided by operating activities	12,838			32,144			56,858			2,302			—			104,142
	Investing Activities
	Purchases of property and equipment	(3,167		)	—			(419		)	(114		)	—			(3,700		)
	Proceeds from sale of business	—			—			18,500			—			—			18,500
	Proceeds from sale of asset	—			—			10,000			—			—			10,000
	Acquisition of Insight Pharmaceuticals, less cash acquired	—			—			(749,666		)	—			—			(749,666		)
	Acquisition of the Hydralyte brand	—			—			—			(77,991		)	—			(77,991		)
	Intercompany activity, net	—			(809,157		)	731,166			77,991			—			—
	Net cash (used in) provided by investing activities	(3,167		)	(809,157		)	9,581			(114		)	—			(802,857		)
	Financing Activities
	Term loan borrowings	—			720,000			—			—			—			720,000
	Term loan repayments	—			(80,000		)	—			—			—			(80,000		)
	Borrowings under revolving credit agreement	—			124,600			—			—			—			124,600
	Repayments under revolving credit agreement	—			(58,500		)	—			—			—			(58,500		)
	Payment of deferred financing costs	—			(16,072		)	—			—			—			(16,072		)
	Proceeds from exercise of stock options	3,654			—			—			—			—			3,654
	Proceeds from exercise of restricted stock exercises	57			—			—			—			—			57
	Excess tax benefits from share-based awards	1,030			—			—			—			—			1,030
	Fair value of shares surrendered as payment of tax withholding	(1,688		)	—			—			—			—			(1,688		)
	Intercompany activity, net	(23,093		)	86,985			(65,950		)	2,058			—			—
	Net cash provided by (used in) financing activities	(20,040		)	777,013			(65,950		)	2,058			—			693,081
	Effect of exchange rate changes on cash and cash equivalents	—			—			—			(746		)	—			(746		)
	(Decrease) increase in cash and cash equivalents	(10,369		)	—			489			3,500			—			(6,380		)
	Cash and cash equivalents - beginning of period	24,644			—			—			3,687			—			28,331
	Cash and cash equivalents - end of period	$	14,275		$	—		$	489		$	7,187		$	—		$	21,951
	Condensed Consolidating Statement of Cash Flows
	Nine Months Ended December 31, 2013
	(In thousands)	Prestige Brands Holdings, Inc.			Prestige			Combined Subsidiary Guarantors			Combined Non-Guarantor Subsidiaries			Eliminations			Consolidated
					Brands,
					Inc.,
					the issuer
	Operating Activities
	Net income (loss)	$	56,614		$	46,941		$	47,279		$	2,867		$	(97,087	)	$	56,614
	Adjustments to reconcile net income (loss) to net cash provided by operating activities:
	Depreciation and amortization	2,017			434			7,624			134			—			10,209
	Deferred income taxes	(33		)	(37		)	10,336			(5		)	—			10,261
	Amortization of deferred financing costs	—			6,023			—			—			—			6,023
	Stock-based compensation costs	3,763			—			—			—			—			3,763
	Loss on extinguishment of debt	—			15,012			—			—			—			15,012
	Premium payment on 2010 Senior Notes Tendered	—			(12,768		)	—			—			—			(12,768		)
Amortization of debt discount	—			3,115			—			—			—			3,115
Loss (gain) on sale or disposal of equipment	—			—			(3		)	—			—			(3		)
Equity in income of subsidiaries	(51,347		)	(41,997		)	(2,867		)	—			96,211			—
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(106		)	(474		)	10,714			(1,639		)	—			8,495
Inventories	—			(3,496		)	2,454			(2,096		)	876			(2,262		)
Prepaid expenses and other current assets	(3,206		)	27			296			100			—			(2,783		)
Accounts payable	462			1,041			(3,375		)	587			—			(1,285		)
Accrued liabilities	(6,550		)	(1,498		)	(5,858		)	375			—			(13,531		)
Net cash provided by operating activities	1,614			12,323			66,600			323			—			80,860
Investing Activities
Purchases of property and equipment	(2,555		)	—			—			(103		)	—			(2,658		)
Proceeds from sale of property and equipment	—			—			3			—			—			3
Acquisition of Care Pharmaceuticals, less cash acquired	—			—			—			(55,215		)	—			(55,215		)
Intercompany activity, net	—			(55,215		)	—			55,215			—			—
Net cash (used in) provided by investing activities	(2,555		)	(55,215		)	3			(103		)	—			(57,870		)
Financing Activities
Proceeds from the issuance of 2013 Senior Notes	—			400,000			—			—			—			400,000
Repayment of 2010 Senior Notes	—			(201,710		)	—			—			—			(201,710		)
Term loan repayments	—			(147,500		)	—			—			—			(147,500		)
Borrowings under revolving credit agreement	—			50,000			—			—			—			50,000
Repayments under revolving credit agreement	—			(45,500		)	—			—			—			(45,500		)
Payment of deferred financing costs	—			(6,933		)	—			—			—			(6,933		)
Proceeds from exercise of stock options	5,738			—			—			—			—			5,738
Excess tax benefits from share-based awards	1,725			—			—			—			—			1,725
Fair value of shares surrendered as payment of tax withholding	(278		)	—			—			—			—			(278		)
Intercompany activity, net	69,683			(5,465		)	(66,603		)	2,385			—			—
Net cash provided by (used in) financing activities	76,868			42,892			(66,603		)	2,385			—			55,542
Effect of exchange rate changes on cash and cash equivalents	—			—			—			151			—			151
Increase in cash and cash equivalents	75,927			—			—			2,756			—			78,683
Cash and cash equivalents - beginning of period	14,720			—			—			950			—			15,670
Cash and cash equivalents - end of period	$	90,647		$	—		$	—		$	3,706		$	—		$	94,353

Business_and_Basis_of_Presenta3

Business and Basis of Presentation (Property and Equipment) (Details)	9 Months Ended
	Dec. 31, 2014
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives		[1]
[1]	Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset.

Business_and_Basis_of_Presenta4

Business and Basis of Presentation (Intangible Assets) (Details)	9 Months Ended
	Dec. 31, 2014
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

Business_and_Basis_of_Presenta5

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%		100.00%
Term of original maturities, cash equivalents, up to and including			3 months
Shipping, warehousing and handling costs	$9.20	$7.60	$26.30	$23.30

Acquisitions_Allocation_of_Ass

Acquisitions Allocation of Assets Acquired and Liabilities Assumed(Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Sep. 03, 2014	Apr. 30, 2014	Jul. 02, 2013
In Thousands, unless otherwise specified
Purchase Price
Goodwill	$291,892	$190,911
Insight Pharmaceuticals
Purchase Price
Cash acquired			3,507
Accounts receivable			25,784
Inventories			23,559
Deferred income tax assets - current			860
Prepaids and other current assets			1,407
Property, plant and equipment			2,308
Goodwill			103,255
Intangible assets			724,374
Total assets acquired			885,054
Accounts payable			16,079
Accrued expenses			8,003
Deferred income tax liabilities - long term			107,799
Total liabilities assumed			131,881
Net assets acquired			753,173
Hydralyte
Purchase Price
Inventories				1,970
Property, plant and equipment				1,267
Goodwill				1,224
Intangible assets				73,580
Total assets acquired				78,041
Accrued expenses				38
Other long term liabilities				12
Total liabilities assumed				50
Net assets acquired				77,991
Care Pharma
Purchase Price
Cash acquired					1,546
Accounts receivable					1,658
Inventories					2,465
Deferred income tax assets - current					283
Prepaids and other current assets					647
Property, plant and equipment					163
Goodwill					23,122
Intangible assets					31,502
Total assets acquired					61,386
Accounts payable					1,537
Accrued expenses					2,788
Other long term liabilities					300
Total liabilities assumed					4,625
Net assets acquired					$56,761

Acquisitions_Narrative_Details

Acquisitions Narrative (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended	6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Sep. 03, 2014	Sep. 30, 2014	Mar. 31, 2014	Apr. 30, 2014	Jul. 02, 2013
					brand
Business Acquisition [Line Items]
Purchased amortizable intangible assets, weighted average remaining period			14 years 1 month
Goodwill	$291,892,000		$291,892,000				$190,911,000
Net income	21,293,000	3,130,000	54,488,000	56,614,000
Insight Pharmaceuticals
Business Acquisition [Line Items]
Purchase price of acquisition					753,200,000
Number of pharmaceutical brands acquired as a result of acquisition					27
Number of brands sold					1
Non-amortizable intangible assets					599,600,000
Amortizable intangible assets					124,800,000
Purchased amortizable intangible assets, weighted average useful life	16 years 2 months 12 days
Purchased amortizable intangible assets, weighted average remaining period	15 years 10 months 12 days
Goodwill					103,255,000
Revenues of acquired business	43,400,000		56,100,000			12,700,000
Net income	3,600,000		1,600,000			-2,000,000
Value of assets sold on acquisition date, excluded from purchase price					18,500,000
Non-amortizable intangible assets					724,374,000
Insight Pharmaceuticals | Intangible assets
Business Acquisition [Line Items]
Value of assets sold on acquisition date, excluded from purchase price					17,700,000
Insight Pharmaceuticals | Inventory
Business Acquisition [Line Items]
Value of assets sold on acquisition date, excluded from purchase price					600,000
Insight Pharmaceuticals | Property, plant and equipment
Business Acquisition [Line Items]
Value of assets sold on acquisition date, excluded from purchase price					200,000
Hydralyte
Business Acquisition [Line Items]
Goodwill								1,224,000
Non-amortizable intangible assets								73,580,000
Care Pharma
Business Acquisition [Line Items]
Non-amortizable intangible assets									29,800,000
Amortizable intangible assets									1,700,000
Purchased amortizable intangible assets, weighted average useful life			15 years 1 month 6 days
Purchased amortizable intangible assets, weighted average remaining period			12 years 0 months 95 days
Goodwill									23,122,000
Non-amortizable intangible assets									$31,502,000

Acquisitions_Pro_Forma_Informa

Acquisitions Pro Forma Information (Details) (Insight Pharmaceuticals, USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Insight Pharmaceuticals
Business Acquisition [Line Items]
Revenues	$593,171	$579,762
Net income	$62,688	$57,537
Earnings per share:
Basic EPS (in dollars per share)	$1.20	$1.12
Diluted EPS (in dollars per share)	$1.19	$1.10

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$98,594	$74,992
Less allowances for discounts, returns and uncollectible accounts	-10,902	-9,942
Accounts receivable, net	87,692	65,050
Trade Accounts Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	95,596	73,632
Other Receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$2,998	$1,360

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
Inventory Disclosure [Abstract]
Packaging and raw materials	$6,909,000	$3,099,000
Finished goods	68,331,000	62,487,000
Inventories	75,240,000	65,586,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$4,400,000	$1,100,000

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
Components of Property and Equipment
Property and equipment, gross	$23,395,000		$23,395,000		$17,442,000
Accumulated depreciation	-10,306,000		-10,306,000		-7,845,000
Property and equipment, net	13,089,000		13,089,000		9,597,000
Depreciation	1,000,000	1,100,000	2,600,000	2,200,000
Machinery
Components of Property and Equipment
Property and equipment, gross	4,313,000		4,313,000		1,927,000
Computer equipment and software
Components of Property and Equipment
Property and equipment, gross	9,950,000		9,950,000		8,923,000
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	2,427,000		2,427,000		1,858,000
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	$6,705,000		$6,705,000		$4,734,000

Goodwill_Details

Goodwill (Details) (USD $)	3 Months Ended	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Sep. 03, 2014	Apr. 30, 2014
		business
Goodwill [Roll Forward]
Balance — March 31, 2014		$190,911,000
Additions		104,478,000
Reductions	-589,000
Effects of foreign currency exchange rates		-2,908,000
Balance — December 31, 2014	291,892,000	291,892,000
Number of acquisitions		2
North American OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2014		160,157,000
Additions		103,254,000
Reductions		0
Effects of foreign currency exchange rates		0
Balance — December 31, 2014	263,411,000	263,411,000
International OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2014		23,365,000
Additions		1,224,000
Reductions		0
Effects of foreign currency exchange rates		-2,908,000
Balance — December 31, 2014	21,681,000	21,681,000
Household Cleaning
Goodwill [Roll Forward]
Balance — March 31, 2014		7,389,000
Additions		0
Reductions		-589,000
Effects of foreign currency exchange rates		0
Balance — December 31, 2014	6,800,000	6,800,000
Insight Pharmaceuticals
Goodwill [Roll Forward]
Balance — March 31, 2014			103,255,000
Balance — December 31, 2014			103,255,000
Hydralyte
Goodwill [Roll Forward]
Balance — March 31, 2014				1,224,000
Balance — December 31, 2014				1,224,000
Comet brand
Additional Information
Gain on sale of brand		$1,300,000

Intangible_Assets_Schedule_of_

Intangible Assets Schedule of Reconciliation of Activity Affecting Intangible Assets (Details) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014	Mar. 31, 2014
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	$1,925,139	$1,925,139
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions	3,900	8,915
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates		-18
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance		1,478,618
Totals, additions		797,954
Totals, reductions		-27,222
Totals, effects of foreign currency exchange rate		-12,568
Totals, gross, ending balance	2,236,782	2,236,782
Intangible Assets, Accumulated Amortization [Abstract]
Totals, accumulated amortization, beginning balance		83,801
Intangible assets, accumulated amortization, additions	3,900	8,915
Totals, accumulated amortization, ending balance	92,698	92,698
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	218,945	218,945
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	2,144,084	2,144,084	1,394,817
North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	1,723,498	1,723,498
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	192,756	192,756
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	1,916,254	1,916,254
International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	91,369	91,369
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	1,330	1,330
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	92,699	92,699
Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	110,272	110,272
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	24,859	24,859
Intangible Assets, Net [Abstract]
Intangible assets, net (excluding goodwill)	135,131	135,131
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		1,273,878
Indefinite-lived Intangible Assets Acquired		673,180
Indefinite Lived Trademarks, reductions		-9,548
Indefinite Lived Trademarks, effects of foreign currency exchange rate		-12,371
Indefinite Lived Trademarks, ending balance	1,925,139	1,925,139
Finite Lived Trademarks
Finite-Lived Intangible Assets, Gross [Abstract]
Finite Lived Trademarks, beginning balance		204,740
Finite Lived Trademarks, additions		124,774
Finite Lived Trademarks, reductions		-17,674
Finite Lived Trademarks, effects of foreign currency exchange rate		-197
Finite Lived Trademarks, ending balance	311,643	311,643
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks, accumulated amortization, beginning balance		83,801
Intangible assets, accumulated amortization, additions		8,915
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates		-18
Finite Lived Trademarks, accumulated amortization, ending balance	92,698	92,698
Intangible Assets, Accumulated Amortization [Abstract]
Intangible assets, accumulated amortization, additions		8,915
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	$218,945	$218,945

Intangible_Assets_Narrative_De

Intangible Assets Narrative (Details) (USD $)	3 Months Ended	9 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Sep. 03, 2014	Apr. 30, 2014
		business
Finite-Lived Intangible Assets [Line Items]
Number of acquisitions		2
Goodwill and intangible asset impairment		$0
Weighted average remaining life for finite-lived intangible assets		14 years 1 month
Amortization expense	3,900,000	8,915,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives		3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives		30 years
Insight Pharmaceuticals
Finite-Lived Intangible Assets [Line Items]
Intangible assets			724,374,000
Acquired intangible assets sold on acquisition date			17,700,000
Weighted average remaining life for finite-lived intangible assets	15 years 10 months 12 days
Hydralyte
Finite-Lived Intangible Assets [Line Items]
Intangible assets				73,580,000
Comet brand
Finite-Lived Intangible Assets [Line Items]
Cash received from licensee as an early buyout option		10,000,000
Gain on sale of brand		1,300,000
Quarterly payments to be received on sale of brand		1,000,000
Pediacare [Member]
Finite-Lived Intangible Assets [Line Items]
Value of reporting unit	$45,800,000	$45,800,000

Intangible_Assets_Expected_Amo

Intangible Assets Expected Amortization Expense (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2015 (Remaining three months ending March 31, 2015)	$3,887
2016	15,547
2017	15,547
2018	15,547
2019	15,547
Thereafter	152,870
Intangible assets, net	$218,945

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Accrued marketing costs	$19,413	$11,812
Accrued compensation costs	6,455	6,232
Accrued broker commissions	1,484	1,019
Income taxes payable	2,163	1,854
Accrued professional fees	2,999	2,002
Deferred rent	1,060	1,258
Accrued production costs	4,390	1,506
Accrued lease termination costs	1,110	0
Other accrued liabilities	1,601	763
Total other accrued liabilities	$40,675	$26,446

LongTerm_Debt_2012_Senior_Note

Long-Term Debt (2012 Senior Notes) (Details) (USD $)	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned	100.00%	100.00%
2012 Senior Notes
Debt Instrument [Line Items]
Debt issuance costs capitalized		12,600,000
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount		250,000,000
Debt instrument, stated interest rate		8.13%

LongTerm_Debt_2012_Term_Loan_a

Long-Term Debt (2012 Term Loan and 2012 ABL Revolver) (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended		3 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2012	Jan. 31, 2012	Mar. 31, 2013	Feb. 21, 2013	Sep. 03, 2014	Dec. 17, 2013
Debt Instrument [Line Items]
Percentage of subsidiary owned					100.00%	100.00%				100.00%
Loss on extinguishment of debt	$0	$15,012,000	$0	$15,012,000
Term Loan and ABL Revolver 2012
Debt Instrument [Line Items]
Debt issuance costs capitalized					20,600,000	20,600,000
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount					660,000,000	660,000,000
Debt instrument, maturity term					7 years
Debt instrument, discount, percentage					1.50%	1.50%
Proceeds from issuance of long-term debt						650,100,000
Debt instrument, quarterly payment, percent of original principal amount									0.25%
Debt instrument, average interest rate during period			5.20%
Term Loans | Amendment 1 2012 Term Loan
Debt Instrument [Line Items]
Loss on extinguishment of debt							1,400,000
Term Loans | Amendment 2 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, reference rate floor									1.00%
Term B-2 | Amendment 2 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount	680,000,000		680,000,000						720,000,000
Debt instrument, reference rate floor									1.00%
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, maturity term					5 years
Line of credit facility, maximum borrowing capacity	135,000,000		135,000,000		50,000,000	50,000,000
Line of credit facility, increase in borrowing capacity	85,000,000		85,000,000
Debt instrument, interest rate, increase (decrease)				-0.25%
Line of credit facility, commitment fee percentage						0.50%
Line of credit facility, conditional commitment fee percentage						0.38%
Line of credit facility, interest rate at period end	3.10%		3.10%
Revolving Credit Facility | 2012 ABL Revolver Amendment 3
Debt Instrument [Line Items]
Line of credit facility, increase in borrowing capacity									40,000,000
LIBOR | Term Loans | Amendment 1 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate								2.75%
Debt instrument, reference rate floor								1.00%
LIBOR | Term Loans | Amendment 2 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate									3.13%
LIBOR | Term B-2 | Amendment 2 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate									3.50%
Debt instrument, step down interest rate									3.25%
LIBOR | Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, variable rate					1.75%	1.75%
Base Rate | Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component					2.00%	2.00%
Base Rate | Term Loans | Amendment 1 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, reference rate floor								2.00%
Base Rate | Term Loans | Amendment 2 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, reference rate floor									2.00%
Base Rate | Term B-2 | Amendment 2 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, reference rate floor									2.00%
Base Rate | Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, variable rate					0.75%	0.75%
Base Rate | Federal Funds Rate | Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component					0.50%	0.50%
Base Rate | Federal Funds Rate | Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component					0.50%	0.50%
Base Rate | LIBOR | Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component					1.00%	1.00%
Base Rate | LIBOR | Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component					1.00%	1.00%
Minimum | LIBOR | Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate						1.00%
Minimum | LIBOR | Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate					2.00%	2.00%
Minimum | Base Rate | Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate					1.00%	1.00%
Maximum | LIBOR | Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate					2.25%	2.25%
Maximum | Base Rate | Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, conditional variable rate					1.25%	1.25%

LongTerm_Debt_2013_Senior_Note

Long-Term Debt (2013 Senior Notes) (Details) (USD $)	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned	100.00%	100.00%
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount	400,000,000
Debt instrument, stated interest rate	5.38%
Debt issuance costs capitalized	7,200,000

LongTerm_Debt_Redemptions_and_

Long-Term Debt (Redemptions and Restrictions) (Details) (USD $)	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Jan. 31, 2012
Debt Instrument [Line Items]
Unamortized debt issuance costs	$30,600,000
Debt instrument, unamortized discount	5,639,000		3,086,000
Repayments of long-term debt	80,000,000	147,500,000
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Unamortized debt issuance expense and discount	9,000,000
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount	101.00%
Unamortized debt issuance expense and discount	6,400,000
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Unamortized debt issuance expense and discount	19,700,000
Prior to February 1, 2016 | Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount				100.00%
Prior to February 1, 2015 | Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount				108.13%
Debt instrument, percentage of principal amount eligible for redemption				35.00%
Upon Change in Control | Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount				101.00%
Prior to December 15, 2016 | Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount	100.00%
Debt instrument, percentage of principal amount eligible for redemption	35.00%
On Or After December 15, 2016 | Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage of principal amount	105.38%
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Unamortized debt issuance expense and discount	1,100,000
Repayments of long-term debt	$66,100,000

LongTerm_Debt_Schedule_of_Long

Long-Term Debt (Schedule of Long-term Debt) (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Long-term debt, gross	$1,643,600	$937,500
Current portion of long-term debt	0	0
Principal amount	1,643,600	937,500
Less: unamortized discount	-5,639	-3,086
Long-term debt, net of unamortized discount	1,637,961	934,414
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	66,100	0
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	400,000	400,000
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	250,000	250,000
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Long-term debt, gross	247,500	287,500
Term Loans | Amendment 2 2012 Term Loan
Debt Instrument [Line Items]
Long-term debt, gross	$680,000	$0

LongTerm_Debt_Maturities_of_Lo

Long-Term Debt (Maturities of Long-term Debt) (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
2015 (remaining three months ending March 31, 2015)	$0
2016	0
2017	66,100
2018	0
2019	247,500
Thereafter	1,330,000
Long-term debt, gross	$1,643,600	$937,500

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Dec. 17, 2013	Jan. 31, 2012	Sep. 03, 2014
Revolving Credit Facility | 2012 ABL Revolver | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	$66,100,000	$65,400,000
Senior Notes | 2013 Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument, face amount			400,000,000
Senior Notes | 2013 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	400,000,000	400,000,000
Senior Notes | 2012 Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument, face amount				250,000,000
Senior Notes | 2012 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	250,000,000	250,000,000
Senior Notes | Nonrecurring | Fair Value, Inputs, Level 2 | 2013 Senior Notes | Market Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	391,500,000	408,500,000
Senior Notes | Nonrecurring | Fair Value, Inputs, Level 2 | 2012 Senior Notes | Market Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	264,100,000	280,600,000
Term Loans | 2012 Term Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument, face amount				660,000,000
Term Loans | 2012 Term Loan | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	247,500,000	287,500,000
Term Loans | Nonrecurring | Fair Value, Inputs, Level 2 | 2012 Term Loan | Market Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	246,900,000	288,900,000
Term B-2 | Amendment 2 2012 Term Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt instrument, face amount	680,000,000				720,000,000
Debt instrument, fair value disclosure	$680,000,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended		9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
Class of Stock [Line Items]
Common stock, shares authorized	250,000,000		250,000,000		250,000,000
Common stock, par value (in USD per share)	0.01		$0.01		$0.01
Preferred stock, shares authorized	5,000,000		5,000,000		5,000,000
Preferred stock, par value (in USD per share)	0.01		$0.01		$0.01
Voting rights, number of votes per common share owned	1		1
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period, shares	781	2,549	48,445	13,275
Restricted stock acquired, average cost per share			$33.66	$27.81

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive (Loss) Income (Components of AOCI) (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Accumulated Other Comprehensive Income [Abstract]
Cumulative translation adjustment	($16,144)	$739
Total accumulated other comprehensive (loss) income, net of tax	($16,144)	$739

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Numerator
Net income	$21,293	$3,130	$54,488	$56,614
Denominator
Denominator for basic earnings per share — weighted average shares outstanding	52,278	51,806	52,110	51,498
Dilutive effect of unvested restricted common stock (including restricted stock units) and options issued to employees and directors	452	639	512	738
Denominator for diluted earnings per share (in shares)	52,730	52,445	52,622	52,236
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$0.41	$0.06	$1.05	$1.10
Diluted net earnings per share (in USD per share)	$0.40	$0.06	$1.04	$1.08

Earnings_Per_Share_Antidilutiv

Earnings Per Share Antidilutive Securities (Details) (Outstanding Stock Awards)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	0.3	0.2	0.3	0.2

ShareBased_Compensation_Narrat

Share-Based Compensation (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Aug. 28, 2014	12-May-14	Mar. 31, 2014
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan	5,000,000		5,000,000
Common stock, par value (in USD per share)	$0.01		$0.01				$0.01
Share-based compensation costs charged against income	$1.50	$1.30	$4.90	$3.80
Tax benefit recognized from share-based compensation expense	0.6	0.4	1.8	1.1
Options, Additional Disclosures:
Options granted, weighted-average grant-date fair value (in USD per share)			$15.93	$13.94
Options exercised, aggregate intrinsic value			8.8
Unrecognized compensation costs related to nonvested awards	5.9		5.9
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition			10 months 24 days
Total fair value of vested shares			4.3	3.2
Cash received from exercise of stock options			3.7	5.7
Tax benefit realized from exercise of stock options			$1.90	$1.70
Shares available for issuance under the Plan	1,200,000		1,200,000
2005 Long-Term Incentive Plan
Share-based Compensation, Aggregate Disclosures:
Share-based compensation arrangement by share-based payment award, number of additional shares authorized					1,800,000
Common stock, par value (in USD per share)					$0.01
Restricted Shares
Restricted Shares
Award vesting period						3 years
Granted in period (in shares)						96,638
Percentage of stock units vesting annually						33.30%
Granted, weighted-average grant-date fair value (in USD per share)			$33.30	$30.19
Restricted Shares | Minimum
Restricted Shares
Award vesting period			3 years
Restricted Shares | Maximum
Restricted Shares
Award vesting period			5 years
Stock Options | Minimum
Restricted Shares
Award vesting period			3 years
Stock Options | Maximum
Restricted Shares
Award vesting period			5 years
Options, Additional Disclosures:
Award exercisability period, from date of grant			10 years
Employee | Restricted Shares
Restricted Shares
Award vesting period			3 years
Employee | Stock Options
Restricted Shares
Award vesting period						3 years
Percentage of stock units vesting annually						33.30%
Options, Additional Disclosures:
Award exercisability period, from date of grant						10 years
Options granted in period						307,490
Options granted, weighted-average grant-date fair value (in USD per share)						33.5
Director | Restricted Shares
Restricted Shares
Award vesting period			1 year
Group One | Restricted Shares
Restricted Shares
Granted in period (in shares)						75,638
Group Two | Restricted Shares
Restricted Shares
Granted in period (in shares)						21,000

ShareBased_Compensation_Restri

Share-Based Compensation Restricted Stock Units Activity) (Details) (Restricted Stock Units (RSUs), USD $)	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock Units (RSUs)
Shares
Outstanding, beginning of period (in shares)	437,500	421,300
Granted (in shares)	104,400	126,600
Vested and issued (in shares)	-122,800	-59,700
Forfeited (in shares)	-21,300	-5,600
Outstanding, end of period (in shares)	397,800	482,600
Vested, end of period (in shares)	76,600	83,100
Weighted- Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)	$16.76	$11.01
Granted, weighted-average grant-date fair value (in USD per share)	$33.30	$30.19
Vested and issued, weighted-average grant-date fair value (in USD per share)	$13.62	$8.42
Forfeited, weighted-average grant-date fair value (in USD per share)	$20.77	$15.11
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)	$21.86	$16.32
Vested, end of period, weighted-average grant-date fair value (in USD per share)	$11.62	$9.63

ShareBased_Compensation_Stock_

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) (Stock Options, USD $)	9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	47.30%	48.00%
Expected dividends	$0	$0
Expected term in years	6 years 0 months	6 years 0 months
Risk-free rate	2.20%	1.30%

ShareBased_Compensation_Stock_1

Share-Based Compensation (Stock Option Activity) (Details) (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Shares
Outstanding, beginning of period (in shares)	994,900	1,386,400
Granted (in shares)	307,500	227,700
Exercised (in shares)	-363,400	-589,900
Forfeited or expired (in shares)	-47,500	-14,200
Outstanding, end of period (in shares)	891,500	1,010,000
Exercisable, end of period (in shares)	335,100	172,100
Weighted- Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$15.24	$10.43
Granted, weighted-average exercise price (in USD per share)	$33.50	$29.94
Exercised, weighted-average exercise price (in USD per share)	$10.05	$9.73
Forfeited or expired, weighted-average exercise price (in USD per share)	$25.76	$14.56
Outstanding, end of period, weighted-average exercise price (in USD per share)	$23.09	$15.18
Exercisable, end of period, weighted-average exercise price (in USD per share)	$15.01	$11.34
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	7 years 10 months 24 days	7 years 7 months 6 days
Exercisable, end of period, weighted-average remaining contractual term	6 years 8 months 12 days	6 years 9 months 18 days
Outstanding, end of period, aggregate intrinsic value	$10,368	$20,828
Exercisable, end of period, aggregate intrinsic value	$6,604	$4,210

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Effective income tax rate	36.50%	25.20%	39.50%	24.60%
One-time benefit due to recent tax law change			$9.10
Net operating loss carryforwards	69.8		69.8
Operating loss carryforwards, limitation on use, annual amount	33.6		33.6
Increase in uncertain tax liability			0.5
Uncertain tax liability	$1.70		$1.70		$1.20

Commitments_and_Contingencies_1

Commitments and Contingencies (Future Minimum Rental Payments) (Details) (USD $)	3 Months Ended			9 Months Ended
	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
		sqft
Operating Leased Assets [Line Items]
Additional space		15,470
2015 (Remaining three months ending March 31, 2015)	$696,000			$696,000
2016	1,923,000			1,923,000
2017	1,849,000			1,849,000
2018	1,856,000			1,856,000
2019	1,864,000			1,864,000
Thereafter	2,465,000			2,465,000
Total future minimum payments due	10,653,000			10,653,000
Rent expense	400,000		400,000	1,200,000	1,200,000
Facilities
Operating Leased Assets [Line Items]
2015 (Remaining three months ending March 31, 2015)	422,000			422,000
2016	1,612,000			1,612,000
2017	1,772,000			1,772,000
2018	1,856,000			1,856,000
2019	1,864,000			1,864,000
Thereafter	2,465,000			2,465,000
Total future minimum payments due	9,991,000			9,991,000
Equipment
Operating Leased Assets [Line Items]
2015 (Remaining three months ending March 31, 2015)	274,000			274,000
2016	311,000			311,000
2017	77,000			77,000
2018	0			0
2019	0			0
Thereafter	0			0
Total future minimum payments due	$662,000			$662,000

Commitments_and_Contingencies_2

Commitments and Contingencies (Long-term Supply Agreement) (Details) (Third-party Manufacturing, USD $)	0 Months Ended
In Thousands, unless otherwise specified	Nov. 01, 2009	Dec. 31, 2014
Third-party Manufacturing
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years
2015 (Remaining three months ending March 31, 2015)		$273
2016		1,074
2017		1,044
2018		1,013
2019		982
Thereafter		560
Total purchase commitment		$4,946

Concentrations_of_Risk_Details

Concentrations of Risk (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
			brand
Concentration Risk [Line Items]
Number of third-party manufacturers	96	58	96	58
Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	44.30%	41.10%	41.90%	41.70%
Number of highest selling brands comprising group against which concentration risk is measured			5
Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	16.50%	20.40%	17.40%	19.70%
Number of customers exceeding concentration risk benchmark			1	1
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			80.10%	86.30%
Number of third-party manufacturers with long-term contracts			44	21
Accounts Receivable | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage			20.20%
Accounts Receivable | Customer Concentration Risk | Walgreens
Concentration Risk [Line Items]
Concentration risk, percentage			13.40%

Business_Segments_Information_

Business Segments (Information on Operating and Reportable Segments) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information, Profit (Loss):
Net sales	$196,435	$143,713	$520,981	$450,862
Other revenues	1,171	1,158	3,596	3,466
Total revenues	197,606	144,871	524,577	454,328
Cost of sales	85,861	64,403	228,424	197,614
Gross profit	111,745	80,468	296,153	256,714
Advertising and promotion	30,144	24,229	74,284	67,457
Contribution margin	81,601	56,239	221,869	189,257
Other operating expenses	24,608	15,781	75,555	45,596
Operating income	56,993	40,458	146,314	143,661
Other expense	23,459	36,272	56,305	68,616
Income before income taxes	33,534	4,186	90,009	75,045
Provision for income taxes	12,241	1,056	35,521	18,431
Net income	21,293	3,130	54,488	56,614
Geographic Concentration Risk | Sales
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage			10.00%	10.00%
Geographic Concentration Risk | Sales | United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	85.90%	85.70%	84.40%	87.20%
Geographic Concentration Risk | Sales | Canada
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	5.10%	8.30%	6.10%	7.80%
Geographic Concentration Risk | Sales | Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	7.20%		7.50%
Geographic Concentration Risk | Goodwill and Intangible Assets | United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage			95.30%
Geographic Concentration Risk | Goodwill and Intangible Assets | Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage			4.70%
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	159,146	115,967	406,831	367,028
Other revenues	151	150	478	450
Total revenues	159,297	116,117	407,309	367,478
Cost of sales	63,479	45,886	158,005	140,419
Gross profit	95,818	70,231	249,304	227,059
Advertising and promotion	26,779	21,380	64,573	61,477
Contribution margin	69,039	48,851	184,731	165,582
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	17,071	8,214	48,093	20,636
Other revenues	4	0	62	14
Total revenues	17,075	8,214	48,155	20,650
Cost of sales	6,247	3,144	17,926	8,947
Gross profit	10,828	5,070	30,229	11,703
Advertising and promotion	2,776	2,145	8,151	3,855
Contribution margin	8,052	2,925	22,078	7,848
Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	20,218	19,532	66,057	63,198
Other revenues	1,016	1,008	3,056	3,002
Total revenues	21,234	20,540	69,113	66,200
Cost of sales	16,135	15,373	52,493	48,248
Gross profit	5,099	5,167	16,620	17,952
Advertising and promotion	589	704	1,560	2,125
Contribution margin	4,510	4,463	15,060	15,827
Operating Segments
Segment Reporting Information, Profit (Loss):
Net sales	197,944	145,222	523,917	453,190
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	160,655	117,476	409,767	369,356
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	17,071	8,214	48,093	20,636
Operating Segments | Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	20,218	19,532	66,057	63,198
Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Net sales	-1,509	-1,509	-2,936	-2,328
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	-1,509	-1,509	-2,936	-2,328
Intersegment Eliminations | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	0	0	0	0
Intersegment Eliminations | Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	$0	$0	$0	$0

Business_Segments_Revenue_by_P

Business Segments (Revenue by Product) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Revenue from External Customer [Line Items]
Revenues	$197,606	$144,871	$524,577	$454,328
Analgesics
Revenue from External Customer [Line Items]
Revenues	28,844	25,765	84,404	83,971
Cough & Cold
Revenue from External Customer [Line Items]
Revenues	35,758	33,601	90,831	88,536
Women's Health
Revenue from External Customer [Line Items]
Revenues	31,953	1,023	42,616	2,644
Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	24,033	19,692	73,663	63,456
Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	23,597	19,217	74,397	63,077
Dermatologicals
Revenue from External Customer [Line Items]
Revenues	18,233	11,516	49,182	44,560
Oral Care
Revenue from External Customer [Line Items]
Revenues	12,472	11,321	35,782	35,611
Other OTC
Revenue from External Customer [Line Items]
Revenues	1,482	2,196	4,589	6,273
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	21,234	20,540	69,113	66,200
North American OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	159,297	116,117	407,309	367,478
North American OTC Healthcare | Analgesics
Revenue from External Customer [Line Items]
Revenues	28,187	25,117	82,290	82,596
North American OTC Healthcare | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	31,927	29,863	76,741	78,791
North American OTC Healthcare | Women's Health
Revenue from External Customer [Line Items]
Revenues	31,364	404	40,851	1,392
North American OTC Healthcare | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	17,365	19,420	58,899	62,873
North American OTC Healthcare | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	19,020	16,973	61,150	56,949
North American OTC Healthcare | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	17,663	11,019	47,383	43,366
North American OTC Healthcare | Oral Care
Revenue from External Customer [Line Items]
Revenues	12,300	11,125	35,421	35,238
North American OTC Healthcare | Other OTC
Revenue from External Customer [Line Items]
Revenues	1,471	2,196	4,574	6,273
North American OTC Healthcare | Household Cleaning
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
International OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	17,075	8,214	48,155	20,650
International OTC Healthcare | Analgesics
Revenue from External Customer [Line Items]
Revenues	657	648	2,114	1,375
International OTC Healthcare | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	3,831	3,738	14,090	9,745
International OTC Healthcare | Women's Health
Revenue from External Customer [Line Items]
Revenues	589	619	1,765	1,252
International OTC Healthcare | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	6,668	272	14,764	583
International OTC Healthcare | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	4,577	2,244	13,247	6,128
International OTC Healthcare | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	570	497	1,799	1,194
International OTC Healthcare | Oral Care
Revenue from External Customer [Line Items]
Revenues	172	196	361	373
International OTC Healthcare | Other OTC
Revenue from External Customer [Line Items]
Revenues	11	0	15	0
International OTC Healthcare | Household Cleaning
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	21,234	20,540	69,113	66,200
Household Cleaning | Analgesics
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Women's Health
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Oral Care
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Other OTC
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Household Cleaning
Revenue from External Customer [Line Items]
Revenues	$21,234	$20,540	$69,113	$66,200

Business_Segments_Assets_by_Se

Business Segments (Assets by Segment) (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$291,892	$190,911
Indefinite-lived intangibles	1,925,139
Finite-lived intangibles	218,945
Intangible assets, net (excluding goodwill)	2,144,084	1,394,817
Intangible assets, net (including goodwill)	2,435,976
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	263,411	160,157
Indefinite-lived intangibles	1,723,498
Finite-lived intangibles	192,756
Intangible assets, net (excluding goodwill)	1,916,254
Intangible assets, net (including goodwill)	2,179,665
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	21,681	23,365
Indefinite-lived intangibles	91,369
Finite-lived intangibles	1,330
Intangible assets, net (excluding goodwill)	92,699
Intangible assets, net (including goodwill)	114,380
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,800	7,389
Indefinite-lived intangibles	110,272
Finite-lived intangibles	24,859
Intangible assets, net (excluding goodwill)	135,131
Intangible assets, net (including goodwill)	$141,931

Condensed_Consolidating_Financ2

Condensed Consolidating Financial Statements Narrative (Details) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Prestige Brands, Inc., the issuer or the borrower
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for equity in income of subsidiaries	($48.10)	($48.10)
Corrections adjustment for cumulative adjustment		1
Prestige Brands Holdings, Inc.
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for equity in income of subsidiaries	0.6	0.6
Eliminations
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for equity in income of subsidiaries	-47.5	-47.5
Combined Subsidiary Guarantors
Condensed Financial Statements, Captions [Line Items]
Corrections adjustment for cumulative adjustment		$1

Condensed_Consolidating_Financ3

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Revenues
Net sales	$196,435	$143,713	$520,981	$450,862
Other revenues	1,171	1,158	3,596	3,466
Total revenues	197,606	144,871	524,577	454,328
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	85,861	64,403	228,424	197,614
Gross profit	111,745	80,468	296,153	256,714
Operating Expenses
Advertising and promotion	30,144	24,229	74,284	67,457
General and administrative	19,454	12,137	63,588	35,390
Depreciation and amortization	5,154	3,644	11,967	10,206
Total operating expenses	54,752	40,010	149,839	113,053
Operating income	56,993	40,458	146,314	143,661
Other (income) expense
Interest income	-20	-16	-67	-44
Interest expense	24,612	21,276	57,505	53,648
Loss on extinguishment of debt	0	15,012	0	15,012
Gain on sale of asset	-1,133	0	-1,133	0
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	23,459	36,272	56,305	68,616
Income before income taxes	33,534	4,186	90,009	75,045
Provision (benefit) for income taxes	12,241	1,056	35,521	18,431
Net income	21,293	3,130	54,488	56,614
Comprehensive income, net of tax:
Currency translation adjustments	-8,779	-2,694	-16,883	-1,571
Total other comprehensive loss	-8,779	-2,694	-16,883	-1,571
Comprehensive income	12,514	436	37,605	55,043
Prestige Brands Holdings, Inc.
Revenues
Net sales	0	0	0	0
Other revenues	0	0	0	0
Total revenues	0	0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	0	0	0	0
Gross profit	0	0	0	0
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	1,408	165	3,662	2,555
Depreciation and amortization	869	983	2,381	2,017
Total operating expenses	2,277	1,148	6,043	4,572
Operating income	-2,277	-1,148	-6,043	-4,572
Other (income) expense
Interest income	-12,226	-12,305	-36,604	-37,296
Interest expense	8,611	8,671	25,788	25,965
Loss on extinguishment of debt		0		0
Gain on sale of asset	0		0
Equity in (income) loss of subsidiaries	-20,462	-1,148	-53,718	-51,347
Total other expense	-24,077	-4,782	-64,534	-62,678
Income before income taxes	21,800	3,634	58,491	58,106
Provision (benefit) for income taxes	507	504	4,003	1,492
Net income	21,293	3,130	54,488	56,614
Comprehensive income, net of tax:
Currency translation adjustments	-8,779	-2,694	-16,883	-1,571
Total other comprehensive loss	-8,779	-2,694	-16,883	-1,571
Comprehensive income	12,514	436	37,605	55,043
Prestige Brands, Inc., the issuer or the borrower
Revenues
Net sales	27,937	25,371	80,514	74,757
Other revenues	83	75	308	210
Total revenues	28,020	25,446	80,822	74,967
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	10,296	9,361	30,170	28,157
Gross profit	17,724	16,085	50,652	46,810
Operating Expenses
Advertising and promotion	2,175	1,748	7,563	8,672
General and administrative	1,879	2,132	7,793	5,256
Depreciation and amortization	156	149	446	434
Total operating expenses	4,210	4,029	15,802	14,362
Operating income	13,514	12,056	34,850	32,448
Other (income) expense
Interest income	-21,602	-14,437	-52,546	-42,765
Interest expense	24,612	21,276	57,505	53,648
Loss on extinguishment of debt		15,012		15,012
Gain on sale of asset	0		0
Equity in (income) loss of subsidiaries	-12,977	-6,845	-33,700	-41,997
Total other expense	-9,967	15,006	-28,741	-16,102
Income before income taxes	23,481	-2,950	63,591	48,550
Provision (benefit) for income taxes	3,782	-2,541	10,761	1,609
Net income	19,699	-409	52,830	46,941
Comprehensive income, net of tax:
Currency translation adjustments	-8,779	-2,694	-16,883	-1,571
Total other comprehensive loss	-8,779	-2,694	-16,883	-1,571
Comprehensive income	10,920	-3,103	35,947	45,370
Combined Subsidiary Guarantors
Revenues
Net sales	155,733	112,662	402,967	361,753
Other revenues	1,166	1,160	3,506	3,454
Total revenues	156,899	113,822	406,473	365,207
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	71,891	53,750	187,218	165,252
Gross profit	85,008	60,072	219,255	199,955
Operating Expenses
Advertising and promotion	25,202	20,336	58,579	55,036
General and administrative	13,760	8,967	43,079	25,782
Depreciation and amortization	3,864	2,440	8,682	7,625
Total operating expenses	42,826	31,743	110,340	88,443
Operating income	42,182	28,329	108,915	111,512
Other (income) expense
Interest income	-1,278	-731	-3,800	-1,441
Interest expense	25,212	18,061	63,350	54,082
Loss on extinguishment of debt		0		0
Gain on sale of asset	-1,133		-1,133
Equity in (income) loss of subsidiaries	-1,654	-999	-2,565	-2,867
Total other expense	21,147	16,331	55,852	49,774
Income before income taxes	21,035	11,998	53,063	61,738
Provision (benefit) for income taxes	6,977	2,720	18,179	14,459
Net income	14,058	9,278	34,884	47,279
Comprehensive income, net of tax:
Currency translation adjustments	-8,779	-2,694	-16,883	-1,571
Total other comprehensive loss	-8,779	-2,694	-16,883	-1,571
Comprehensive income	5,279	6,584	18,001	45,708
Combined Non-Guarantor Subsidiaries
Revenues
Net sales	14,273	7,502	40,436	16,174
Other revenues	266	10	1,104	1,112
Total revenues	14,539	7,512	41,540	17,286
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	5,208	2,325	14,998	6,461
Gross profit	9,331	5,187	26,542	10,825
Operating Expenses
Advertising and promotion	2,767	2,145	8,142	3,749
General and administrative	2,407	873	9,054	1,797
Depreciation and amortization	265	72	458	130
Total operating expenses	5,439	3,090	17,654	5,676
Operating income	3,892	2,097	8,888	5,149
Other (income) expense
Interest income	-15	-6	-55	-30
Interest expense	1,278	731	3,800	1,441
Loss on extinguishment of debt		0		0
Gain on sale of asset	0		0
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	1,263	725	3,745	1,411
Income before income taxes	2,629	1,372	5,143	3,738
Provision (benefit) for income taxes	975	373	2,578	871
Net income	1,654	999	2,565	2,867
Comprehensive income, net of tax:
Currency translation adjustments	-8,779	-2,694	-16,883	-1,571
Total other comprehensive loss	-8,779	-2,694	-16,883	-1,571
Comprehensive income	-7,125	-1,695	-14,318	1,296
Eliminations
Revenues
Net sales	-1,508	-1,822	-2,936	-1,822
Other revenues	-344	-87	-1,322	-1,310
Total revenues	-1,852	-1,909	-4,258	-3,132
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	-1,534	-1,033	-3,962	-2,256
Gross profit	-318	-876	-296	-876
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
Total operating expenses	0	0	0	0
Operating income	-318	-876	-296	-876
Other (income) expense
Interest income	35,101	27,463	92,938	81,488
Interest expense	-35,101	-27,463	-92,938	-81,488
Loss on extinguishment of debt		0		0
Gain on sale of asset	0		0
Equity in (income) loss of subsidiaries	35,093	8,992	89,983	96,211
Total other expense	35,093	8,992	89,983	96,211
Income before income taxes	-35,411	-9,868	-90,279	-97,087
Provision (benefit) for income taxes	0	0	0	0
Net income	-35,411	-9,868	-90,279	-97,087
Comprehensive income, net of tax:
Currency translation adjustments	26,337	8,082	50,649	4,713
Total other comprehensive loss	26,337	8,082	50,649	4,713
Comprehensive income	($9,074)	($1,786)	($39,630)	($92,374)

Condensed_Consolidating_Financ4

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Condensed Financial Statements, Captions [Line Items]
Ownership percentage	100.00%
Current assets
Cash and cash equivalents	$21,951	$28,331	$94,353	$15,670
Accounts receivable, net	87,692	65,050
Inventories	75,240	65,586
Deferred income tax assets	8,346	6,544
Prepaid expenses and other current assets	7,533	11,674
Total current assets	200,762	177,185
Property and equipment, net	13,089	9,597
Goodwill	291,892	190,911
Intangible assets, net	2,144,084	1,394,817
Other long-term assets	30,769	23,153
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	2,680,596	1,795,663
Current liabilities
Accounts payable	38,567	48,286
Accrued interest payable	11,792	9,626
Other accrued liabilities	40,675	26,446
Total current liabilities	91,034	84,358
Long-term debt
Principal amount	1,643,600	937,500
Less unamortized discount	-5,639	-3,086
Long-term debt, net of unamortized discount	1,637,961	934,414
Deferred income tax liabilities	342,385	213,204
Other long-term liabilities	279	327
Intercompany payables	0	0
Total Liabilities	2,071,659	1,232,303
Stockholders' Equity
Common stock	525	520
Additional paid-in capital	423,985	414,387
Treasury stock, at cost	-3,062	-1,431
Accumulated other comprehensive (loss) income, net of tax	-16,144	739
Retained earnings (accumulated deficit)	203,633	149,145
Total Stockholders' Equity	608,937	563,360
Total Liabilities and Stockholders' Equity	2,680,596	1,795,663
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	14,275	24,644	90,647	14,720
Accounts receivable, net	7	473
Inventories	0	0
Deferred income tax assets	329	260
Prepaid expenses and other current assets	2,183	8,004
Total current assets	16,794	33,381
Property and equipment, net	9,752	8,966
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	1,208,881	655,146
Investment in subsidiary	1,529,929	1,497,357
Total Assets	2,765,356	2,194,850
Current liabilities
Accounts payable	1,956	4,416
Accrued interest payable	0	0
Other accrued liabilities	8,738	7,728
Total current liabilities	10,694	12,144
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	2,145,725	1,619,346
Total Liabilities	2,156,419	1,631,490
Stockholders' Equity
Common stock	525	520
Additional paid-in capital	423,985	414,387
Treasury stock, at cost	-3,062	-1,431
Accumulated other comprehensive (loss) income, net of tax	-16,144	739
Retained earnings (accumulated deficit)	203,633	149,145
Total Stockholders' Equity	608,937	563,360
Total Liabilities and Stockholders' Equity	2,765,356	2,194,850
Prestige Brands, Inc., the issuer or the borrower
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	14,376	14,245
Inventories	8,976	14,357
Deferred income tax assets	759	925
Prepaid expenses and other current assets	253	113
Total current assets	24,364	29,640
Property and equipment, net	187	112
Goodwill	66,007	66,007
Intangible assets, net	192,459	192,861
Other long-term assets	30,769	23,153
Intercompany receivables	2,642,233	1,824,482
Investment in subsidiary	1,217,930	749,947
Total Assets	4,173,949	2,886,202
Current liabilities
Accounts payable	5,006	7,658
Accrued interest payable	11,792	9,626
Other accrued liabilities	2,343	2,117
Total current liabilities	19,141	19,401
Long-term debt
Principal amount	1,643,600	937,500
Less unamortized discount	-5,639	-3,086
Long-term debt, net of unamortized discount	1,637,961	934,414
Deferred income tax liabilities	58,475	56,827
Other long-term liabilities	0	0
Intercompany payables	998,359	451,497
Total Liabilities	2,713,936	1,462,139
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,280,948	1,280,945
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	-16,144	739
Retained earnings (accumulated deficit)	195,209	142,379
Total Stockholders' Equity	1,460,013	1,424,063
Total Liabilities and Stockholders' Equity	4,173,949	2,886,202
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	489	0	0	0
Accounts receivable, net	65,113	45,885
Inventories	61,169	46,309
Deferred income tax assets	6,762	4,914
Prepaid expenses and other current assets	4,365	2,898
Total current assets	137,898	100,006
Property and equipment, net	1,970	226
Goodwill	204,205	101,540
Intangible assets, net	1,858,708	1,169,943
Other long-term assets	0	0
Intercompany receivables	869,979	656,759
Investment in subsidiary	73,633	34,562
Total Assets	3,146,393	2,063,036
Current liabilities
Accounts payable	27,884	33,553
Accrued interest payable	0	0
Other accrued liabilities	25,494	13,443
Total current liabilities	53,378	46,996
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	283,874	156,327
Other long-term liabilities	0	0
Intercompany payables	1,518,457	1,037,105
Total Liabilities	1,855,709	1,240,428
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,131,578	681,503
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	-16,144	739
Retained earnings (accumulated deficit)	175,250	140,366
Total Stockholders' Equity	1,290,684	822,608
Total Liabilities and Stockholders' Equity	3,146,393	2,063,036
Combined Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	7,187	3,687	3,706	950
Accounts receivable, net	8,196	4,447
Inventories	6,403	5,930
Deferred income tax assets	496	445
Prepaid expenses and other current assets	732	659
Total current assets	23,014	15,168
Property and equipment, net	1,180	293
Goodwill	21,680	23,364
Intangible assets, net	92,917	32,013
Other long-term assets	0	0
Intercompany receivables	9,417	13,595
Investment in subsidiary	0	0
Total Assets	148,208	84,433
Current liabilities
Accounts payable	3,721	2,659
Accrued interest payable		0
Other accrued liabilities	4,100	3,158
Total current liabilities	7,821	5,817
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	36	50
Other long-term liabilities	279	327
Intercompany payables	67,969	42,034
Total Liabilities	76,105	48,228
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	74,031	23,815
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	-16,144	739
Retained earnings (accumulated deficit)	14,216	11,651
Total Stockholders' Equity	72,103	36,205
Total Liabilities and Stockholders' Equity	148,208	84,433
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Inventories	-1,308	-1,010
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	-1,308	-1,010
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	-4,730,510	-3,149,982
Investment in subsidiary	-2,821,492	-2,281,866
Total Assets	-7,553,310	-5,432,858
Current liabilities
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized discount	0	0
Long-term debt, net of unamortized discount	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	-4,730,510	-3,149,982
Total Liabilities	-4,730,510	-3,149,982
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	-2,486,557	-1,986,263
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	48,432	-2,217
Retained earnings (accumulated deficit)	-384,675	-294,396
Total Stockholders' Equity	-2,822,800	-2,282,876
Total Liabilities and Stockholders' Equity	($7,553,310)	($5,432,858)

Condensed_Consolidating_Financ5

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Operating Activities
Net income (loss)	$54,488	$56,614
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	11,967	10,209
Gain on sale of asset	-1,133	0
Deferred income taxes	19,517	10,261
Amortization of deferred financing costs	4,568	6,023
Stock-based compensation costs	4,919	3,763
Loss on extinguishment of debt	0	15,012
Premium payment on 2010 Senior Notes Tendered	0	-12,768
Amortization of debt discount	1,336	3,115
Lease termination costs	1,125	0
Loss (gain) on sale or disposal of equipment	321	-3
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	2,113	8,495
Inventories	14,478	-2,262
Prepaid expenses and other current assets	7,598	-2,783
Accounts payable	-25,452	-1,285
Accrued liabilities	8,297	-13,531
Net cash provided by operating activities	104,142	80,860
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of property and equipment	-3,700	-2,658
Proceeds from sale of property and equipment	0	3
Proceeds from sale of business	18,500	0
Proceeds from sale of asset	10,000	0
Acquisition of Insight Pharmaceuticals, less cash acquired	-749,666	0
Acquisition of the Hydralyte brand	-77,991	0
Acquisition of Care Pharmaceuticals, less cash acquired	0	-55,215
Intercompany activity, net	0	0
Net cash used in investing activities	-802,857	-57,870
Financing Activities
Term loan borrowings	720,000	0
Proceeds from the issuance of 2013 Senior Notes	0	400,000
Repayment of 2010 Senior Notes	0	-201,710
Term loan repayments	-80,000	-147,500
Repayments under revolving credit agreement	-58,500	-45,500
Borrowings under revolving credit agreement	124,600	50,000
Payment of deferred financing costs	-16,072	-6,933
Proceeds from exercise of stock options	3,654	5,738
Proceeds from restricted stock exercises	57	0
Excess tax benefits from share-based awards	1,030	1,725
Fair value of shares surrendered as payment of tax withholding	-1,688	-278
Intercompany activity, net	0	0
Net cash provided by financing activities	693,081	55,542
Effects of exchange rate changes on cash and cash equivalents	-746	151
(Decrease) increase in cash and cash equivalents	-6,380	78,683
Cash and cash equivalents - beginning of period	28,331	15,670
Cash and cash equivalents - end of period	21,951	94,353
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	54,488	56,614
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	2,381	2,017
Gain on sale of asset	0
Deferred income taxes	-69	-33
Amortization of deferred financing costs	0	0
Stock-based compensation costs	4,919	3,763
Loss on extinguishment of debt		0
Premium payment on 2010 Senior Notes Tendered		0
Amortization of debt discount	0	0
Lease termination costs	0
Loss (gain) on sale or disposal of equipment	0	0
Equity in income of subsidiaries	-53,718	-51,347
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	466	-106
Inventories	0	0
Prepaid expenses and other current assets	5,821	-3,206
Accounts payable	-2,460	462
Accrued liabilities	1,010	-6,550
Net cash provided by operating activities	12,838	1,614
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of property and equipment	-3,167	-2,555
Proceeds from sale of property and equipment		0
Proceeds from sale of business	0
Proceeds from sale of asset	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of the Hydralyte brand	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net	0	0
Net cash used in investing activities	-3,167	-2,555
Financing Activities
Term loan borrowings	0
Proceeds from the issuance of 2013 Senior Notes		0
Repayment of 2010 Senior Notes		0
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	3,654	5,738
Proceeds from restricted stock exercises	57
Excess tax benefits from share-based awards	1,030	1,725
Fair value of shares surrendered as payment of tax withholding	-1,688	-278
Intercompany activity, net	-23,093	69,683
Net cash provided by financing activities	-20,040	76,868
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) increase in cash and cash equivalents	-10,369	75,927
Cash and cash equivalents - beginning of period	24,644	14,720
Cash and cash equivalents - end of period	14,275	90,647
Prestige Brands, Inc., the issuer or the borrower
Operating Activities
Net income (loss)	52,830	46,941
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	446	434
Gain on sale of asset	0
Deferred income taxes	1,814	-37
Amortization of deferred financing costs	4,568	6,023
Stock-based compensation costs	0	0
Loss on extinguishment of debt		15,012
Premium payment on 2010 Senior Notes Tendered		-12,768
Amortization of debt discount	1,336	3,115
Lease termination costs	0
Loss (gain) on sale or disposal of equipment	0	0
Equity in income of subsidiaries	-33,700	-41,997
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	-131	-474
Inventories	5,381	-3,496
Prepaid expenses and other current assets	-140	27
Accounts payable	-2,652	1,041
Accrued liabilities	2,392	-1,498
Net cash provided by operating activities	32,144	12,323
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of property and equipment	0	0
Proceeds from sale of property and equipment		0
Proceeds from sale of business	0
Proceeds from sale of asset	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of the Hydralyte brand	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net	-809,157	-55,215
Net cash used in investing activities	-809,157	-55,215
Financing Activities
Term loan borrowings	720,000
Proceeds from the issuance of 2013 Senior Notes		400,000
Repayment of 2010 Senior Notes		-201,710
Term loan repayments	-80,000	-147,500
Repayments under revolving credit agreement	-58,500	-45,500
Borrowings under revolving credit agreement	124,600	50,000
Payment of deferred financing costs	-16,072	-6,933
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	86,985	-5,465
Net cash provided by financing activities	777,013	42,892
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) increase in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	34,884	47,279
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	8,682	7,624
Gain on sale of asset	-1,133
Deferred income taxes	17,900	10,336
Amortization of deferred financing costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt		0
Premium payment on 2010 Senior Notes Tendered		0
Amortization of debt discount	0	0
Lease termination costs	1,125
Loss (gain) on sale or disposal of equipment	0	-3
Equity in income of subsidiaries	-2,565	-2,867
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	6,556	10,714
Inventories	8,109	2,454
Prepaid expenses and other current assets	2,070	296
Accounts payable	-21,748	-3,375
Accrued liabilities	2,978	-5,858
Net cash provided by operating activities	56,858	66,600
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of property and equipment	-419	0
Proceeds from sale of property and equipment		3
Proceeds from sale of business	18,500
Proceeds from sale of asset	10,000
Acquisition of Insight Pharmaceuticals, less cash acquired	-749,666
Acquisition of the Hydralyte brand	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net	731,166	0
Net cash used in investing activities	9,581	3
Financing Activities
Term loan borrowings	0
Proceeds from the issuance of 2013 Senior Notes		0
Repayment of 2010 Senior Notes		0
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	-65,950	-66,603
Net cash provided by financing activities	-65,950	-66,603
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) increase in cash and cash equivalents	489	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	489	0
Combined Non-Guarantor Subsidiaries
Operating Activities
Net income (loss)	2,565	2,867
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	458	134
Gain on sale of asset	0
Deferred income taxes	-128	-5
Amortization of deferred financing costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt		0
Premium payment on 2010 Senior Notes Tendered		0
Amortization of debt discount	0	0
Lease termination costs	0
Loss (gain) on sale or disposal of equipment	321	0
Equity in income of subsidiaries	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	-4,778	-1,639
Inventories	692	-2,096
Prepaid expenses and other current assets	-153	100
Accounts payable	1,408	587
Accrued liabilities	1,917	375
Net cash provided by operating activities	2,302	323
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of property and equipment	-114	-103
Proceeds from sale of property and equipment		0
Proceeds from sale of business	0
Proceeds from sale of asset	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of the Hydralyte brand	-77,991
Acquisition of Care Pharmaceuticals, less cash acquired		-55,215
Intercompany activity, net	77,991	55,215
Net cash used in investing activities	-114	-103
Financing Activities
Term loan borrowings	0
Proceeds from the issuance of 2013 Senior Notes		0
Repayment of 2010 Senior Notes		0
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	2,058	2,385
Net cash provided by financing activities	2,058	2,385
Effects of exchange rate changes on cash and cash equivalents	-746	151
(Decrease) increase in cash and cash equivalents	3,500	2,756
Cash and cash equivalents - beginning of period	3,687	950
Cash and cash equivalents - end of period	7,187	3,706
Eliminations
Operating Activities
Net income (loss)	-90,279	-97,087
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	0	0
Gain on sale of asset	0
Deferred income taxes	0	0
Amortization of deferred financing costs	0	0
Stock-based compensation costs	0	0
Loss on extinguishment of debt		0
Premium payment on 2010 Senior Notes Tendered		0
Amortization of debt discount	0	0
Lease termination costs	0
Loss (gain) on sale or disposal of equipment	0	0
Equity in income of subsidiaries	89,983	96,211
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	0	0
Inventories	296	876
Prepaid expenses and other current assets	0	0
Accounts payable	0	0
Accrued liabilities	0	0
Net cash provided by operating activities	0	0
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchases of property and equipment	0	0
Proceeds from sale of property and equipment		0
Proceeds from sale of business	0
Proceeds from sale of asset	0
Acquisition of Insight Pharmaceuticals, less cash acquired	0
Acquisition of the Hydralyte brand	0
Acquisition of Care Pharmaceuticals, less cash acquired		0
Intercompany activity, net	0	0
Net cash used in investing activities	0	0
Financing Activities
Term loan borrowings	0
Proceeds from the issuance of 2013 Senior Notes		0
Repayment of 2010 Senior Notes		0
Term loan repayments	0	0
Repayments under revolving credit agreement	0	0
Borrowings under revolving credit agreement	0	0
Payment of deferred financing costs	0	0
Proceeds from exercise of stock options	0	0
Proceeds from restricted stock exercises	0
Excess tax benefits from share-based awards	0	0
Fair value of shares surrendered as payment of tax withholding	0	0
Intercompany activity, net	0	0
Net cash provided by financing activities	0	0
Effects of exchange rate changes on cash and cash equivalents	0	0
(Decrease) increase in cash and cash equivalents	0	0
Cash and cash equivalents - beginning of period	0	0
Cash and cash equivalents - end of period	$0	$0